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ABSTRACT
Multidrug resistance (MDR) in cancer cells is a challenging phenomenon often 
associated with P-glycoprotein (Pgp) surface expression. Finding new ways to 
bypass Pgp-mediated MDR still remains a daunting challenge towards the successful 
treatment of malignant neoplasms such as colorectal cancer.
We applied the Cell Surface Capture technology to chemosensitive and 
chemoresistant human colon cancer to explore the cell surface proteome of Pgp-
expressing cells in a discovery-driven fashion. Comparative quantitative analysis of 
identified cell surface glycoproteins revealed carbonic anhydrase type XII (CAXII) to be 
up-regulated on the surface of chemoresistant cells, similarly to Pgp. In cellular models 
showing an acquired MDR phenotype due to the selective pressure of chemotherapy, 
the progressive increase of the transcription factor hypoxia-inducible factor-1 alpha 
was paralleled by the simultaneous up-regulation of Pgp and CAXII. CAXII and Pgp 
physically interacted at the cell surface. CAXII silencing or pharmacological inhibition 
with acetazolamide decreased the ATPase activity of Pgp by altering the optimal pH at 
which Pgp operated and promoted chemosensitization to Pgp substrates in MDR cells.
We propose CAXII as a new secondary marker of the MDR phenotype that 
influences Pgp activity directly and can be used as a pharmacological target for MDR 
research and potential treatment.
INTRODUCTION
One of the main features of chemoresistant cancer 
cells is the high cell surface expression of ATP binding 
cassette (ABC) transporters, such as P-glycoprotein (Pgp/
ABCB1), multidrug resistance (MDR) related proteins 
(MRPs/ABCCs) and breast cancer resistance protein 
(BCRP/ABCG2). These plasma membrane transporters 
enable the active transport of chemotherapeutic drugs into 
the extracellular space, ultimately reducing intracellular 
concentrations, cytotoxicity, and therapeutic success 
[1–3]. Pgp is one of the ABC transporters with the broadest 
spectrum of substrates, which include anthracyclines, 
taxanes, Vinca alkaloids, epipodophyllotoxins, topotecan, 
methotrexate, imatinib, dasatinib, lapatinib, gefitinib, 
sorafenib, and erlotinib. As a consequence, tumors 
overexpressing Pgp often exhibit a MDR phenotype and 
are difficult to eradicate by chemotherapy [1, 4].
In attempts to overcome chemoresistance, ABC 
transporters have been targeted with pharmacological 
inhibitors. However, such approaches have led to several 
therapeutic failures due to the widespread tissue distribution 
of ABC transporters. Moreover, since ABC transporters play 
critical functions in the physiological clearance of catabolites 
and xenobiotics [5–7], their pharmacological inhibition 
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produces toxicities in vivo. Thus, pharmacological targeting 
of other surface proteins that are selectively overexpressed 
in chemoresistant cells and modulate the activity of ABC 
transporters is a promising alternative approach.
Until now, only few studies have analyzed the 
surfaceome of chemoresistant cells [8, 9]. These studies 
have identified proteins that were overexpressed in MDR 
cells, such as CD44 [8], dihydropyridine receptor alpha 
2 and laminin subunit alpha 5 [9]. These cell surface 
proteins could be of clinical utility as potential biomarkers 
predictive of chemoresistance and/or potential therapeutic 
targets. However, these proteins were not found to 
modulate the expression or activity of Pgp or other ABC 
transporters in MDR cells, making them unlikely targets 
for the suppression of the MDR phenotype.
Pgp activity is finely modulated by the plasma-
membrane lipid composition and physicochemical 
parameters [10]. A considerable number of proteins have 
been reported to physically interact with Pgp, such as the 
E3 ubiquitin ligases RNF2 [11] and FBXO15 [12], the 
endoplasmic reticulum-associated chaperon calreticulin 
[13], the serine/threonine kinase Pim-1 [14], the estrogen 
receptor repressor prohibitin 2 [15], the transcription 
factor Myc [16], the surface molecules caveolin-1 [17] 
and CD4 [18], the BRCA2 and CDKN1A-interacting 
protein BCCP, the Target of Rapamycin complex 2 subunit 
MAPKAP1 [18], and the lysosomal-associated protein 
LAPTM4B-35 [19]. Among these interactors, caveolin-1 
[17] and RNF2 [11] negatively modulate Pgp activity, 
whereas LAPTM-35 is the only protein that has been 
shown to increase Pgp activity [19].
Here, we applied the Cell Surface Capturing 
(CSC) technology to investigate the surfaceome of 
a Pgp-negative (chemosensitive) and Pgp-positive 
(chemoresistant) human colon cancer model system, 
with the goal to identify quantitative surfaceome changes 
indicative of chemoresistance. This analysis identified 
carbonic anhydrase type XII (CAXII; accession number 
O43570, UniProtKB; http://www.uniprot.org) as a protein 
with significantly higher expression on the surface of 
chemoresistant cells. Based on this finding, we investigated 
whether changes in CAXII cell surface abundance were 
able to induce and/or maintain the MDR phenotype 
and whether CAXII could potentially be exploited as 
therapeutic target to chemosensitize MDR cells.
RESULTS
CAXII shows a higher cell surface abundance in 
chemoresistant cells than in chemosensitive cells
CSC technology, which selectively tags and purifies 
cell surface exposed glycopeptides for analysis by mass 
spectrometry, enabled the identification of 380 cell surface 
residing glycoproteins from human chemosensitive colon 
cancer HT29 cells and human chemoresistant colon cancer 
HT29/dx cells. The functional classification of the identified 
proteins is shown in Figure 1A. The quantitative analysis of 
cell surface protein expression in HT29/dx and in HT29 
cells is reported in Figure 1B and in Supplemental Table 1.
Among the ABC transporters detected on the 
surface of chemoresistant cells, ABCC1/MRP1 was more 
abundant on HT29/dx cells, and ABCC3/MRP3, ABCA1, 
ABCA2 showed lower expression levels. One of the 
proteins with highest relative expression in chemoresistant 
cells was CAXII, which was 16-fold more expressed in 
HT29/dx cells than in parental HT29 cells (Figure 1B and 
Supplemental Table 1). CAXII topology and identified 
glycopeptides are shown in Supplemental Figure 1. These 
data were confirmed by confocal microscopy analysis 
(Figure 2A) and by immunoblot analysis of biotinylated 
extracts from HT29 and HT29/dx cells (Figure 2B). 
Biotinylation assays confirmed that Pgp and MRP1 were 
more abundant on the surface of HT29/dx compared to 
HT29 cells (Figure 2B). The ratio of N-glycosylated 
to deglycosylated Pgp in plasma membrane extracts 
was about 1 in HT29/dx cells, whereas the ratio of 
N-glycosylated to deglycosylated MRP1 was higher than 
1 (Supplemental Figure  2A and 2B).
The higher surface abundance level of CAXII was 
not due to differential trafficking, since intracellular pools 
of CAXII were also elevated in HT29/dx whole cell lysate 
(Figure 2C). This phenomenon was not specific to colon 
cancer cells and higher levels of CAXII were also found 
in chemoresistant lung cancer A549/dx cells compared 
to chemosensitive A549 cells (Figure 2C). Similarly, 
a comparison of U2-OS cells with corresponding 
doxorubicin-resistant clones (U2-OS/dx 30, U2-OS/
dx 100, U2-OS/dx 580) revealed that CAXII levels also 
correlated with chemoresistance in these osteosarcoma 
cells (Figure 2C). All tested chemoresistant cell lines 
had higher expression of Pgp than the corresponding 
chemosensitive cells; HT29/dx and A549/dx cells also 
had higher levels of MRP1, which was undetectable in 
the chemoresistant osteosarcoma cells (Figure 2C). On the 
basis of these results, we found a strong direct correlation 
between CAXII and Pgp expression (Figure 2D); no 
correlation was found for CAXII and MRP1 expression 
(not shown). According to tissues expression data, CAXII 
and Pgp (Supplemental Figure 3 and 4), but not CAXII 
and MRP1 (Supplemental Figure 3 and 5), were expressed 
at similar levels in colon adenocarcinoma samples.
CAXII expression increases during the 
acquisition of chemoresistance, in parallel with 
the increase of HIF-1α and Pgp
The difference in CAXII protein expression 
between HT29 and HT29/dx cells was paralleled by a 
striking difference in mRNA levels (Figure 3A). Upstream 
regulatory regions of the CAXII gene contain hypoxia-
response element (HRE) sequences [20], suggesting that the 
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Figure 1: CSC technology enables the identification and quantitative comparison of the surface glycoproteome of 
human chemosensitive and chemoresistant colon cancer cells. (A) 380 identified plasma membrane-associated proteins (black 
bars) from human chemosensitive colon cancer HT29 cells and human chemoresistant colon cancer HT29/dx cells were categorized 
according to the biological function assigned by the PANTHER algorithm. (B) Quantitative analysis of the proteins detected by CSC 
technology. The ratio between protein expressed in HT29/dx cells and protein expressed in HT29 cells is represented by a colorimetric 
logarithmic scale. CAXII, ABCC1/MRP1, ABCC3/MRP3, ABCA1 and ABCA2 hits are indicated.
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Figure 2: Expression of CAXII in chemosensitive and chemoresistant human cancer cells. Human chemosensitive 
colon cancer HT29 cells and their chemoresistant counterpart HT29/dx cells, human chemosensitive lung cancer A549 cells and their 
chemoresistant counterpart A549/dx cells, human chemosensitive osteosarcoma U2-OS cells and the chemoresistant clones U2-OS/dx 
30, U2-OS/dx 100, U2-OS/dx 580 were subjected to the following assays. (A) Confocal microscope analysis of HT29 and HT29/dx 
cells stained for CAXII. The samples were analyzed by laser scanning confocal microscope for green fluorescence signal (CAXII) or by 
Nomarski differential interference contrast (DIC) optics. Magnification: 60 × objective; 10 × ocular lens. Bar = 20 μm. (B) Western blot 
analysis of biotinylated plasma membrane associated CAXII, Pgp and MRP1 in HT29 and HT29/dx cells. The pan-cadherin expression was 
used as a control of equal protein loading. The figure is representative of three experiments with similar results. (C) Whole cell lysates were 
analyzed by Western blotting for the expression of CAXII, Pgp and MRP1. The β-tubulin expression was used as a control of equal protein 
loading. The figure is representative of three experiments with similar results. (D) Linear regression analysis between CAXII and Pgp 
expression. The mean band density of CAXII and Pgp (panel C), expressed as arbitrary units, was calculated by ImageJ software (http://
www.rsb.info.nih.gov/ij/). r coefficient was calculated using Fig. P software (Fig. P Software Inc., Hamilton, Canada).
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transcription factor hypoxia inducible factor-1α (HIF-1α) 
might be involved in the control of CAXII expression. HIF-
1α activity was undetectable in HT29 cells, but present in 
HT29/dx where the protein was bound to HRE-containing 
DNA probes even under normoxic conditions (Figure 
3B). In the chemoresistant cells, this leads to increased 
transcription of HIF-1α target genes, such as glucose 
transporter 1, hexokinase, aldolase-A, glyceraldehyde 
3-phosphate dehydrogenase, phosphoglycerate kinase, 
enolase-A, lactate dehydrogenase, vascular endothelial 
growth factor, erythropoietin in the chemoresistant cells 
(Supplemental Figure 6). Moreover, HT29/dx cells had 
significantly higher levels of HIF-1α mRNA, together 
with increased levels of CAXII and Pgp mRNA, a 
known target gene of HIF-1α [21], than HT29 cells 
(Figure 3C–3E). Interestingly, HIF-1α silencing in HT29/
dx cells (Figure 3C) produced a strong reduction of both 
CAXII (Figure 3D) and Pgp mRNA (Figure 3E), without 
affecting cell proliferation, apoptosis and viability of these 
cells (not shown).
The selection of chemoresistant cells from 
parental chemosensitive HT29 cells with increasing 
concentrations of doxorubicin induced a progressive 
increase of HIF-1α mRNA, measured every 5 passages 
of cell culture during the selection process (Figure 4A). 
The observed HIF-1α increase was paralleled by the 
progressive increase in CAXII (Figure 4B) and Pgp 
(Figure 4C) mRNA, and by the progressive decrease 
in the accumulation of doxorubicin (Figure 4D), a 
substrate of Pgp.
Figure 3: CAXII and Pgp expression levels are affected by HIF-1α in chemoresistant cells. (A) The CAXII mRNA level 
in HT29 and HT29/dx cells was detected by qRT-PCR. Data are presented as means ± SD (n = 4). Versus HT29: *p < 0.001. (B) EMSA 
detection of HIF-1α bound to its DNA consensus sequence was performed on nuclear extracts of normoxic HT29 and HT29/dx cells. 
Hypoxic HT29 cells (grown at 2% O2 for 24 h) were used as positive control of HIF-1α activation (+). One lane was loaded with distilled 
water in place of cell extracts and was used as negative control (−). As control of specificity, the nuclear extracts of hypoxic HT29 cells 
were incubated with an anti-HIF-1α antibody (Ab HIF-1α). The band corresponding to the HIF-1α-DNA complex is indicated by the arrow. 
The figure is representative of three experiments with similar results. (C–E) mRNA was extracted from wild-type HT29 cells and HT29/
dx cells (CTRL), HT29/dx cells treated with a non targeting scrambled siRNA (scr) or with a HIF-1α-targeting specific siRNA pool (siHIF) 
for 24 h. The expression of HIF-1α (panel C), CAXII (panel D) and Pgp (panel E) was detected by qRT-PCR. Data are presented as means 
± SD (n = 4). Versus CTRL HT29: *p < 0.001; versus CTRL HT29/dx: ° p < 0.001.
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Depletion of CAXII does not affect proliferation 
and survival of chemoresistant cells
To investigate the functional role of CAXII in 
chemoresistant cells, we produced a HT29/dx subclone 
silenced for CAXII (Figure 5A). HT29 and HT29/dx 
cells did not show any appreciable difference in terms of: 
cell proliferation, as revealed by the proportion of Ki67-
positive cells (Figure 5B); spontaneous apoptotic cell death, 
as indicated by the percentage of annexin V-fluorescein 
isothiocyanate (FITC)/propidium iodide (PI)-positive cells 
(Figure 5C); autophagy, as indicated by the expression level 
of classical autophagic markers such as beclin, ATG12 
and LC3B (Figure 5D). Interestingly, untreated HT29/
dx cells appeared more senescent than parental HT29 
cells, as suggested by higher staining with β-galactosidase 
(Figure 5E). Despite the documented role of CAXII as a pro-
oncogenic factor [22], enzyme silencing did not alter any 
of these parameters in chemoresistant cells (Figure 5B–5E).
CAXII is associated with Pgp and is necessary to 
maintain Pgp-mediated chemoresistance
Confocal microscope analysis showed that 
CAXII and Pgp co-localized on HT29/dx cells plasma 
membrane (Figure 6A). In co-immunoprecipitation 
assays, we found that CAXII was physically associated 
with Pgp, but not with MRP1 on HT29/dx cells plasma 
membrane (Figure 6B). CAXII co-immunoprecipitated 
with both glycosylated and deglycosylated Pgp 
(Supplemental Figure 7A). In some cell lines 
deglycosylated Pgp is less active, but in HT29/dx the 
glycosylation status of Pgp did not affect its ATPase 
activity (Supplemental Figure 7B).
These observations raised the question whether 
CAXII directly affected the activity of Pgp. Supporting 
this hypothesis, CAXII silencing in HT29/dx cells led to 
a dramatic decrease in Pgp ATPase activity (Figure 6C). 
As expected, HT29/dx cells accumulated significantly less 
doxorubicin than HT29 cells. In contrast, CAXII-silenced 
HT29/dx cells showed significantly increased levels of 
intracellular doxorubicin, reaching the same amount 
measured in HT29 cells (Figure 6D), where Pgp was 
undetectable (Figure 2C). In keeping with the different 
expression levels of Pgp, chemotherapeutic drugs that 
are substrates of Pgp, such as doxorubicin and irinotecan 
[23], reduced cell viability of HT29 cells, but not HT29/dx 
cells. However, both doxorubicin and irinotecan exhibited 
cytotoxic effects on HT29/dx cells silenced for CAXII 
(Figure 6E).
Figure 4: CAXII increases during the acquisition of chemoresistance. HT29 cells were cultured in medium containing 
increasing concentrations of doxorubicin, as detailed under Methods. (A–C) At passage (P) 1, 5, 10, 15, 20 the mRNA was extracted and the 
expression of HIF-1α (panel A), CAXII (panel B) and Pgp (panel C) was detected by qRT-PCR. Data are presented as means ± SD (n = 4). 
Versus P1: *p < 0.001. (D) An aliquot of cells was incubated 24 h with 5 μmol/L doxorubicin, then lysed and analyzed for the intracellular 
doxorubicin content. Data are presented as means ± SD (n = 4). Versus P1: *p < 0.001.
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Figure 5: Depletion of CAXII does not affect proliferation and survival of chemoresistant cells. HT29/dx cells were 
cultured for 48 h with fresh medium (CTRL), treated with a non targeting scrambled siRNA (scr) or with a CAXII-targeting specific siRNA 
pool (siCAXII). HT29 cells were included as control. (A) The expression of CAXII was measured in whole cell lysates by Western blotting. 
The β-tubulin expression was used as a control of equal protein loading. The figure is representative of three experiments with similar 
results. (B) Confocal microscope analysis of cells stained for the proliferation marker Ki67. The samples were analyzed by laser scanning 
confocal microscopy for Ki67 protein signal (green fluorescence) or for PI (red fluorescence), used to visualize nuclei. Magnification: 
60 × objective; 10 × ocular lens. Bar = 20 μm. (C) The percentage of cells positive to annexin V-FITC, as index of early apoptosis, and 
to PI, as index of late apoptosis, was measured by flow cytometry. Percentages indicate annexin V-positive cells (lower right quadrant),  
PI-positive cells (upper left quadrant), annexin V/PI-positive cells (upper right quadrant). The figures are representative of three experiments 
with similar results. (D) Western blot analysis of the autophagy markers beclin, ATG12 and LC3B. The β-tubulin expression was used as 
a control of equal protein loading. The figure is representative of three experiments with similar results. (E) Cells were fixed and stained 
for β-galactosidase activity, then examined by fluorescence microscopy. Magnification: 20 × objective; 10 × ocular lens. Bar = 100 μm.
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Figure 6: CAXII is physically associated with Pgp and increases Pgp activity in chemoresistant cells. (A) Confocal 
microscope analysis of HT29 and HT29/dx cells stained for CAXII and Pgp. The samples were analyzed by laser scanning confocal 
microscope for green (CAXII) or red (Pgp) fluorescence signal. Magnification: 60 × objective; 10 × ocular lens. Bar = 20 μm. (B) 
Biotinylated plasma membrane-derived extracts from HT29 and HT29/dx cells were immunoprecipitated (IP) with anti-Pgp or anti-
MRP1 antibodies, then immunoblotted (IB) with anti-CAXII, anti-Pgp or anti-MRP1 antibodies. no Ab: samples immunoprecipitated 
without antibody. The figure is representative of three experiments with similar results. (C) HT29/dx cells were cultured for 48 h with 
fresh medium (CTRL), treated with a non targeting scrambled siRNA (scr) or with a CAXII-targeting specific siRNA pool (siCAXII). 
The Pgp ATPase activity was measured spectrophotometrically on Pgp-rich vesicles extracted from membrane fractions. Data are 
presented as means ± SD (n = 4). Versus CTRL: *p < 0.001. (D) Cells treated as reported in C were incubated for 24 h with 5 μmol/L 
doxorubicin, then the intracellular drug content was measured fluorimetrically. HT29 were included as control of chemosensitive cells. 
Data are presented as means ± SD (n = 4). Versus HT29 CTRL: *p < 0.001; versus HT29/dx CTRL: ° p < 0.001. (E) Cells treated as 
reported in C were grown for 72 h in fresh medium (CTRL), or in medium containing 5 μmol/L doxorubicin (DOX) or 1 μM irinotecan 
(CPT11), then stained with neutral red dye. The absorbance of viable cells was measured spectrophotometrically. Data are presented 
as means ± SD (n = 4). For HT29 and HT29/dx cells, versus CTRL: *p < 0.001; for HT29/dx cells, versus wild type HT29/dx DOX or 
HT29/dx CPT11, respectively: ° p < 0.002. 
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The association between Pgp and CAXII was shared 
by other chemoresistant cells, such as lung cancer A549/
dx cells and osteosarcoma resistant clones (Figure 6F). In 
analogy to HT29/dx cells, CAXII silencing (Supplemental 
Figure 8) reduced Pgp ATPase activity in these cell lines 
(Figure 6G).
CAIX is another isoform of carbonic anhydrase. 
This isoform is known to be highly expressed in tumors, 
including colon cancer, and has been linked to tumor 
aggressiveness and resistance to therapy [20]. This led 
us to investigate the expression levels of CAIX in our 
model system. In HT29 cells, CAIX mRNA levels were 
higher than the ones of CAXII, but were not increased in 
HT29/dx cells, where levels were significantly lower than 
for CAXII (Figure 7A). CAIX protein was detectable in 
HT29 and HT29/dx cells, without differences between 
chemosensitive and chemoresistant cells, both in whole 
cell lysates and in plasma membrane-derived extracts 
(Figure 7B). In contrast to CAXII (Figure 6B), CAIX did 
not co-immunoprecipitate with Pgp in plasma membrane 
extracts (Figure 7C). Moreover, CAIX-silenced HT29/
dx cells (Figure 7D) retained the same low amount of 
intracellular doxorubicin than wild-type HT29/dx cells 
(Figure 7E), suggesting that CAIX is not involved in the 
chemosensitization towards Pgp substrates.
Pharmacological inhibition of CAXII restores 
chemosensitivity in chemoresistant cancer cells
Similarly to the effect of CAXII silencing, the 
CAXII inhibitor acetazolamide (Ki 5.6 + 0.2 nM) [24] 
dose-dependently reduced the activity of Pgp (Figure 
8A), suggesting that the activity of CAXII is critical 
for the catalytic activity of the transporter. At 1 μmol/L, 
acetazolamide, which was devoid of effects in HT29 cells 
where CAXII and Pgp were hardly detectable by Western 
blot (Figure 2B–2C), significantly increased the retention of 
doxorubicin (Figure 8B) and restored the cytotoxic effects 
of doxorubicin and irinotecan in HT29/dx cells (Figure 8C).
The activity of CAIX and CAXII has been reported 
to induce intracellular alkalinization [25]. As shown in 
Figure 8D, the pHi of HT29 was 7.39 + 0.02, whereas 
the pHi of HT29/dx was 7.58 + 0.03. To investigate 
whether CAXII contributes to this different pHi between 
chemosensitive and chemoresistant cells, we measured 
the pHi in HT29/dx cells silenced for CAXII or treated 
with acetazolamide: interestingly, these experimental 
conditions lowered the pHi of HT29/dx cells to values 
similar to HT29 cells. By contrast, acetazolamide did 
not affect the pHi of low CAXII-expressing HT29 cells 
(Figure 8D). To evaluate whether such different pHi 
conditions may affect the activity of Pgp, we measured the 
ATPase activity of Pgp from HT29/dx plasma membrane 
in buffers with different pH. We did not detect changes 
in the basal ATPase activity of Pgp; by contrast, the 
verapamil-stimulated ATPase activity of Pgp, taken as 
an index of the transporter’s maximal activity, increased 
from pH 7.0 to pH 7.6 (Figure 8E), suggesting that the 
optimal pH at which Pgp operates is slightly alkaline (i.e. 
compatible with the pHi of HT29/dx cells) and that the pH 
produced by CAXII inhibition likely lowered Pgp activity.
DISCUSSION
In this work we analyzed the surfaceome of 
chemosensitive Pgp-negative and chemoresistant Pgp-
positive human colon cancer cells and identified CAXII 
more highly expressed in the latter.
CAXII is a surface-associated enzyme highly 
expressed in tumors of renal [26], ovarian [27] and 
colorectal [28] origin, where it maintains the homeostasis 
of HCO3
− [29].
Figure 6: (Continued) (F) Biotinylated plasma membrane-derived extracts from human chemosensitive lung cancer A549 cell 
and chemoresistant A549/dx cells, human chemosensitive osteosarcoma U2-OS cells and chemoresistant U2-OS/dx580 cells were 
immunoprecipitated (IP) with an anti-Pgp antibody, then immunoblotted (IB) with an anti-CAXII or an anti-Pgp antibody. no Ab: samples 
immunoprecipitated without antibody. The figure is representative of two experiments with similar results. (G) A549/dx and U2-OS/dx580 
cells were grown in fresh medium (CTRL), treated with a non targeting scrambled siRNA (scr) or with a CAXII-targeting specific siRNA 
pool (siCAXII). The Pgp ATPase activity was measured spectrophotometrically on Pgp-rich vesicles extracted from membrane fractions. 
Data are presented as means ± SD (n = 3). For both cell lines, versus CTRL: *p < 0.001.
Oncotarget6785www.impactjournals.com/oncotarget
Figure 7: CAIX does not mediate chemoresistance to Pgp substrates in colon cancer cells. (A) The CAIX mRNA level 
in HT29 and HT29/dx cells was detected by qRT-PCR. CAXII mRNA level is shown for comparison. Data are presented as means ± SD  
(n = 4). Versus HT29: *p < 0.001; for both HT29 and HT29/dx cells, CAIX versus CAXII expression: ° p < 0.001. (B) Western blot 
analysis of CAIX expression in whole cell lysates (upper panel; Total) and biotinylated plasma membrane-derived extracts (lower panel; 
Surface) in HT29 and HT29/dx cells. The β-tubulin and pan-cadherin expression were used as controls of equal protein loading in whole 
cell lysates and plasma membrane-derived extracts, respectively. The figure is representative of three experiments with similar results. 
(C) Biotinylated plasma membrane-derived extracts from HT29 and HT29/dx cells were immunoprecipitated (IP) with an anti-Pgp 
antibody, then immunoblotted (IB) with an anti-CAIX or an anti-Pgp antibody. no Ab: samples immunoprecipitated without antibody. The 
figure is representative of three experiments with similar results. (D) HT29/dx cells were cultured for 48 h with fresh medium (CTRL), 
treated with a non targeting scrambled siRNA (scr) or with a CAIX-targeting specific siRNA pool (siCAIX). HT29 cells were included as 
control. The expression of CAIX was measured in whole cell lysates by Western blotting. The β-tubulin expression was used as a control of 
equal protein loading. The figure is representative of three experiments with similar results. (E) HT29/dx cells treated as reported in D were 
incubated for 24 h with 5 μmol/L doxorubicin, then the intracellular drug content was measured fluorimetrically. HT29 cells were included 
as control of chemosensitive cells. Data are presented as means ± SD (n = 4). Versus HT29 CTRL: *p < 0.001.
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Figure 8: Effects of acetazolamide on Pgp activity, chemosensitivity and intracellular pH in chemoresistant cancer 
cells. (A) Pgp-rich vesicles were extracted from membrane fractions of HT29/dx cells, then the Pgp ATPase activity was measured 
spectrophotometrically in the absence (0) or in the presence of increasing concentrations of acetazolamide (AZA), added during the assay. 
Data are presented as means ± SD (n = 4). Versus 0: *p < 0.005. (B) HT29 and HT29/dx were incubated for 24 h with 5 μmol/L doxorubicin 
(DOX). When indicated, 1 μmol/L acetazolamide (AZA) was co-incubated. The intracellular doxorubicin retention was measured 
fluorimetrically. Data are presented as means ± SD (n = 4). HT29/dx DOX cells versus HT29 DOX cells: *p < 0.001; HT29/dx DOX+AZA 
cells versus HT29/dx DOX cells: ° p < 0.005. (C) Cells were grown for 72 h in fresh medium (CTRL), or in medium containing 1 μM 
acetazolamide (AZA), 5 μmol/L doxorubicin (DOX), 1 μM irinotecan (CPT11), alone or in combination, then stained with neutral red dye. 
The absorbance of viable cells was measured spectrophotometrically. Data are presented as means ± SD (n = 4). For HT29 cells, versus 
CTRL: *p < 0.001; for HT29/dx cells, versus CTRL: ° p < 0.05. (D) The intracellular pH (pHi) measurement was performed in duplicate 
(n = 4) on HT29 and HT29/dx cells untreated or treated with a non targeting scrambled siRNA (scr), with a CAXII-targeting specific siRNA 
pool (siCAXII) for 48 h, with 1 μmol/L acetazolamide (AZA) for 24 h. Significance versus HT29 cells: *p < 0.01; versus HT29/dx cells: 
° p < 0.02. (E) The Pgp ATPase activity was measured spectrophotometrically in Pgp-rich vesicles extracted from HT29/dx cell membrane 
fractions, using buffers with different pH, in the absence (open circles) or presence (solid circles) of 10 μmol/L verapamil, chosen as a Pgp 
activator. Data are presented as means ± SD (n = 4).
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In our model of chemoresistant colon cancer cells, 
CAXII was increased at both the protein and mRNA 
level, suggesting that CAXII gene transcription was up-
regulated. The presence of HRE sequences in upstream 
regions of the CAXII gene, and the down-regulation of 
CAXII mRNA in cells expressing the Von Hippel Lindau 
protein, a HIF-1α-inhibitor [20], led us to the hypothesis 
that HIF-1α might be involved in the control of CAXII 
expression. In HT29/dx cells, HIF-1α was constitutively 
active even under normoxia, as demonstrated by its 
constitutive binding of hypoxia-responsive DNA elements, 
and by higher expression levels of its classical target 
genes. This characteristic was progressively acquired 
during the selection of resistant clones from the parental 
chemosensitive population exposed to doxorubicin. 
Although we have previously reported the constitutive 
activation of HIF-1α in normoxic cancer cells with a 
stable MDR phenotype [30], the parallel increase in HIF-
1α transcription and the progressive acquisition of MDR 
is a new observation. This trend may be due to the use of 
doxorubicin as selective agent: indeed, in normoxia the 
drug produces reactive oxygen species [31] that increase 
HIF-1α [32]. During the onset of the MDR phenotype, 
the increase of HIF-1α was paralleled by an increase of 
CAXII and Pgp mRNAs. These data suggest that HIF-1α 
may play a role in the up-regulation of CAXII in HT29/
dx cells. Since the relative increase of CAXII mRNA was 
greater than for classical target genes of HIF-1α, other 
transcription factors and co-activators induced during the 
selection of chemoresistant clones – in addition to HIF-
1α – are likely to be involved in the up-regulation of the 
CAXII gene.
In previous reports, CAXII overexpression has 
been associated with good [33, 34] or poor [35, 36] 
prognosis, depending on the tumor type. Furthermore, 
the protein has been reported to support cell proliferation 
and invasion, based on the observations that a monoclonal 
antibody against CAXII reduced tumor growth [22] and 
that CAXII inhibitors lowered metastatic potential [37] 
in mouse xenografts. However, according to the results 
obtained by CAXII silencing in HT29/dx cells, CAXII 
did not confer any selective advantage in terms of cell 
proliferation, spontaneous necrotic/apoptotic death, 
autophagy or senescence rate. By contrast, we found 
that CAXII promoted the acquisition and maintenance of 
chemoresistance.
In our study, Pgp and MRP1 were found to be 
up-regulated on the plasma membrane of HT29/dx 
cells. Whereas CSC technology successfully identified 
MRP1, it failed to identify Pgp. The gel shift of the 
MRP1 band upon treatment with Peptide-N-Glycosidase 
F (PNGase F) was bigger than the gel shift of the Pgp 
band, suggesting that the extent of glycosylation was 
higher in MRP1. This makes MRP1 easier to detect by 
CSC, which specifically identifies N-glycopeptides of 
cell surface proteins. Moreover, Pgp was highly abundant 
in its deglycosylated form in HT29/dx cells. Of note, 
CAXII was physically associated with both glycosylated 
and deglycosylated Pgp, which were equally active. 
We did not further investigate which domain of CAXII 
may be responsible for the interaction with Pgp. Pgp 
has a large intracellular domain (Supplemental Figure 
9) and according to the crystal structure of CAXII, the 
intracellular C-terminal domain of the enzyme is likely 
to be responsible for the interactions with other proteins, 
the oligomerization of CAXII, the catalytic activity and 
the signal transduction [38].
In all chemoresistant cells tested in this study, 
CAXII appeared to support Pgp activity: CAXII-silenced 
cells showed a decreased ATPase activity of Pgp, an 
increased retention of the Pgp substrate doxorubicin, and 
a restored cytotoxicity of doxorubicin and irinotecan.
However, we cannot exclude that other tumor-
associated CA isoforms are involved in the onset or 
maintenance of chemoresistance. For instance, the 
overexpression of CAIX has been correlated with a low 
response to doxorubicin treatment in breast cancer patients 
[39]. In our model, CAIX was expressed at similar levels 
in HT29 and HT29/dx cells. Furthermore, it seemed 
to play a minor role in the resistance to doxorubicin as 
illustrated by the fact that CAIX-silenced HT29/dx cells 
had the same low intracellular retention of doxorubicin 
than wild-type HT29/dx cells. What about the resistance 
phenotype?
It has previously been reported that the verapamil-
stimulated activity of Pgp, considered an index of the 
maximal activity of the transporter, increases at slightly 
alkaline pH [40]. We confirmed this trend in Pgp-rich 
vesicles extracted from HT29/dx cells. The pHi measured 
in HT29/dx cells was lowered by CAXII silencing or by 
pharmacological CAXII inhibition with acetazolamide, 
suggesting that CAXII may contribute to maintain the 
slightly alkaline pHi of chemoresistant cells. A slightly 
alkaline pHi has been shown to induce resistance to 
doxorubicin in HT29/dx cells [41]. Furthermore, it has 
been reported that the activity of both CAIX and CAXII 
regulate the pHi homeostasis in cancer cells [25]. In our 
experiments, the selective silencing of CAIX and CAXII 
in HT29/dx cells suggested that only the latter was 
involved in the maintenance of doxorubicin resistance in 
this model. Since CAIX did not physically interact with 
Pgp, we hypothesize that it did not produce a sufficient 
alkalinization to reduce the transporter’s efflux activity 
in the plasma membrane area where Pgp is localized. 
By contrast, the co-localization of Pgp and CAXII may 
favor the optimal pH condition for Pgp activity in the 
microenvironment where Pgp and CAXII are concentrated.
Our work shows that pharmacological inhibition 
of CAXII with acetazolamide effectively sensitizes 
resistant cells to the cytotoxic effects of Pgp substrates. 
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Acetazolamide has antitumor activity in vivo [42] and 
increases doxorubicin cytotoxicity in HT29 cells under 
hypoxia [43].
Since acetazolamide is being used in clinical 
practice as a diuretic, our work – although based on 
in vitro experiments – may have translational potential 
in the future. Given the role of CAXII in tumor growth 
and invasion, selective inhibitors of CAXII are under 
active development as new anticancer drugs [44–46], 
in particular against hypoxic tumors [47]. We propose 
that these synthetic and more selective inhibitors might 
be used as chemosensitizing agents for the treatment of 
Pgp overexpressing tumors. To achieve a more selective 
targeting of tumor cells, liposome- or nanoparticle-based 
carriers, which increase the intratumor accumulation of 
drugs, either by passive targeting (i.e. by the enhanced 
permeability retention effect) or active targeting [48], 
represent a valid approach. Our proteomic screening 
showed that, besides CAXII, a considerable number of 
other surface antigens were expressed at significantly 
higher levels in MDR cells. Some of these proteins may 
represent suitable targets for liposomes carrying CAXII 
inhibitors for the active and more selective targeting of 
chemoresistant colon cancer cells in preclinical models.
In summary, we show for the first time that CAXII 
is more highly abundant at the plasma membrane of Pgp-
positive chemoresistant cells and is increased in parallel 
with Pgp during the acquisition of chemoresistance. Since 
CAXII activity is necessary for the optimal activity of Pgp, 
CAXII inhibitors may represent promising therapeutic 
tools to overcome Pgp-mediated chemoresistance.
METHODS
Chemicals
The plasticware for cell cultures was obtained 
from Falcon (Becton Dickinson, Franklin Lakes, NJ). 
The electrophoresis reagents were obtained from Bio-
Rad Laboratories (Hercules, CA). The protein content 
of cell lysates was assessed with the BCA kit from 
Sigma Chemicals Co. (St. Louis, MO). Unless specified 
otherwise, all reagents were purchased from Sigma 
Chemicals Co.
Cells
Human chemosensitive colon cancer HT29 cells 
(from ATCC, Manassas, VA) were cultured in RPMI 1640 
medium. A subpopulation, called HT29/dx, was created 
by culturing parental cells with 12.5 nmol/L doxorubicin 
for passages 1–5, 25 nmol/L doxorubicin for passages 
6–10, 50 nmol/L doxorubicin for passages 11–15, 100 
nmol/L doxorubicin for passages 16–20, then stably 
maintaining cells in RPMI 1640 medium containing 200 
nmol/L doxorubicin. HT29-dx cells displayed a higher 
abundance of Pgp, MRP1 and BCRP, and were cross-
resistant to doxorubicin and irinotecan [49]. Human 
chemosensitive lung cancer A549 cells (ATCC) and the 
chemoresistant A549/dx cell subline were obtained and 
cultured as reported [50]. Human doxorubicin sensitive 
osteosarcoma U2-OS cells and the corresponding clones 
with increasing resistance to doxorubicin (U2-OS/dx 30, 
U2-OS/dx 100, U2-OS/dx 580), selected by culturing 
U2-OS cells in a medium with 30, 100, 580 ng/mL 
doxorubicin, were a kind gift from Dr. Massimo Serra, 
Laboratory of Experimental Oncology (IRCCS Istituto 
Ortopedico Rizzoli, Bologna, Italy), and have been 
previously characterized [51].
Surface glycoprotein identification via CSC 
technology
Cells were prepared for CSC as described 
elsewhere [52]. Briefly, cells were treated for 15 min at 
4°C in the dark with 2 mmol/L sodium meta-periodate 
(Thermo Fisher Scientific Inc., Waltham, MA) in PBS, 
pH 6.5, then washed and incubated with 6.5 mmol/L 
biocytin hydrazide (Biotium, Hayward, CA) in PBS, 
pH 6.5, for 1 h to biotinylate oxidized carbohydrates 
of cell surface glycoproteins. Cells were washed, 
incubated on ice in hypotonic lysis buffer (10 mmol/L 
Tris, 0.5 mmol/L MgCl2, 10 mmol/L iodoacetamide, 
pH 7.5) for 10 min, homogenized for 10 s using a 
Dounce homogenizer. Afterward cell debris and nuclei 
were removed by centrifugation at 1 700 x g for 7 
min. The supernatant was solubilized in 400 μL of 
digestion buffer (100 mmol/L NH
4
HCO3, 1 mmol/L 
iodoacetamide, 1 mmol/L 2,2′-thiodiethanol, 0.1% w/v 
RapiGest; Waters, Milan, Italy) and sonicated with a 
VialTweeter instrument (Hielscher Ultrasonic GmbH, 
Teltow, Germany). Proteins were digested overnight with 
trypsin in a protease:protein ratio of 1:100. After protein 
digestion, the peptide mixture was heated at 95°C for 10 
min to inactivate trypsin, then biotinylated glycopeptides 
were bound to Streptavidin Plus UltraLink Resin (SA 
beads; Pierce, Rockford, IL) for 3 h at 37°C. After 
extensive washing, cysteine containing peptides, which 
were bound via a disulfide bridge to the biotinylated 
glycopeptides, were eluted from the SA beads by 
incubation with elution buffer (100 mmol/L NH
4
HCO3, 
10 mmol/L tris(2-carboxyethyl)phosphine, 1 mmol/L 
dithiothreitol) for 1 h at room temperature. SA beads 
were washed again and N-linked glycopeptides were 
enzymatically released from the SA beads in a second 
overnight elution step in the presence of PNGase F. The 
free thiols of cysteine containing peptides were alkylated 
with iodoacetamide. Peptides were desalted on Ultra 
MicroTIP Columns (The Nest Group, Southborough, 
MA) and dried in a SpeedVac concentrator. Finally, 
peptides were solubilized in LC-MS grade water 
containing 0.1% v/v formic acid and 5% v/v acetonitrile. 
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MS/MS spectra were acquired with a LTQ Orbitrap XL 
mass spectrometer, converted to mzXML and searched 
against the UniProt database (Version 57.15) using 
the SEQUEST algorithm. Statistical data analysis was 
performed using a combination of ISB (Institute of 
Systems Biology, Seattle, WA) open-source software 
tools (PeptideProphetTM, ProteinProphetTM, TPP 
Version 4.3.1). A ProteinProphet probability score of at 
least 0.9 was used for data-filtering (corresponding to 
a false discovery rate of 1%). The protein functional 
classification was performed using the PANTHER 
algorithm (http://www.pantherdb.org). Quantitative data 
analysis was performed using the XPRESS software.
Western blot analysis
For whole cell lysates, the cells were rinsed 
with ice-cold lysis buffer (50 mmol/L Tris, 10 mmol/L 
EDTA, 1% v/v Triton-X100), supplemented with the 
protease inhibitor cocktail set III (80 μmol/L aprotinin, 
5 mmol/L bestatin, 1.5 mmol/L leupeptin, 1 mmol/L 
pepstatin; Calbiochem, San Diego, CA), 2 mmol/L 
phenylmethylsulfonyl fluoride and 1 mmol/L Na3VO4, 
then sonicated and centrifuged at 13 000 x g for 10 min at 
4oC. 20 μg protein extracts were subjected to SDS-PAGE 
and probed with the following antibodies: anti-CAXII 
(Abcam, Cambridge, UK); anti-CAIX (Novus Biologicals, 
Littleton, CO); anti-Pgp (C219, Calbiochem); anti-MRP1 
(Abcam); anti-beclin (Abcam); anti-ATG12 (Abcam); anti-
LC3B (Abcam); anti-β-tubulin (Santa Cruz Biotechnology 
Inc., Santa Cruz, CA), followed by a peroxidase-
conjugated secondary antibody (Bio-Rad Laboratories). 
The membranes were washed with Tris-buffered saline-
Tween 0.1% v/v, and the proteins were detected by 
enhanced chemiluminescence (Bio-Rad Laboratories). 
Plasma membrane-associated CAXII was evaluated 
in biotinylation assays, using the Cell Surface Protein 
isolation kit (Thermo Fisher Scientific Inc.), as previously 
reported [53], using an anti pan-cadherin antibody (Santa 
Cruz Biotechnology Inc.) to check the equal protein 
loading. In co-immunoprecipitation experiments, 100 μg 
of proteins were immunoprecipitated with the anti-Pgp or 
anti-MRP1 antibodies, using the PureProteome protein A 
and protein G Magnetic Beads (Millipore, Billerica, MA). 
The immunoprecipitated proteins were separated by SDS-
PAGE and probed with the anti-CAXII, anti-CAIX, anti-
Pgp or anti-MRP1 antibodies, followed by a peroxidase-
conjugated secondary antibody. To detect glycosylated 
and deglycosyated proteins, biotinylated extracts (100 
μg) were heated at 99°C for 10 min to denature proteins, 
then incubated for 1 h at 37°C in the absence or presence 
of 1 μU of human recombinant PNGaseF. Samples were 
resolved by SDS-PAGE and probed with the following 
antibodies, recognizing both the glycosylated and the 
deglycosylated forms: anti-Pgp (3C3.2, Millipore); anti-
MRP1 (Enzo Life Sciences, Farmingdale, NY).
Confocal microscopy analysis
5 × 105 cells were grown on sterile glass coverslips, 
rinsed and fixed with 4% w/v paraformaldehyde for 15 
min. To visualize surface CAXII and Pgp, the samples 
were washed with PBS and stained with an anti-
CAXII antibody or an anti-Pgp antibody conjugated to 
phycoerythrin (Millipore) for 1 h. After washing, samples 
stained for CAXII were incubated with an AlexaFluor 
488-conjugated secondary antibody (Millipore) for 1 h and 
re-washed. The coverslips were mounted with 4 μL of Gel 
Mount Aqueous Mounting and examined with an Olympus 
FV300 laser scanning confocal microscope (Olympus 
Biosystems, Tokyo, Japan). For each experimental point, 
a minimum of five microscopic fields were examined.
Quantitative real time-PCR (qRT-PCR)
Total RNA was extracted and reverse-transcribed 
using the QuantiTect Reverse Transcription Kit (Qiagen, 
Hilden, Germany). The qRT-PCR was performed with 
the IQTM SYBR Green Supermix (Bio-Rad Laboratories). 
The same cDNA preparation was used to quantify the 
genes of interest and the housekeeping gene S14. The 
primer sequences, designed using the qPrimerDepot 
database (http://primerdepot.nci.nih.gov/), are reported 
in the Supplemental Table 2. The relative quantification 
was performed by comparing each PCR product with the 
housekeeping PCR product, using the Bio-Rad Software 
Gene Expression Quantitation (Bio-Rad Laboratories).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as previously reported 
[54]. The probe containing the HIF-1α oligonucleotide 
consensus sequence was labeled with [γ-32P]-ATP (3,000 
Ci/μmol, 250 mCi; Amersham International, Little 
Chalfont, UK), using T4 polynucleotide kinase (Roche, 
Basel, Switzerland). Oligonucleotide sequence was 
5′-TCTGTACGTGACCACACTCACCTC-3′. For each 
extract, 10 μg was incubated for 20 min with 20 000 cpm 
of [32P]-labeled double-stranded oligonucleotide at 4°C. In 
the supershift assay, nuclear extracts were pre-incubated 
for 30 min at room temperature with 2 μL of an anti-HIF-
1α antibody (Millipore); the reaction mixture containing 
the [32P]-labeled double-stranded oligonucleotide was 
then added. The DNA-protein complex was separated on 
a non denaturating 4% polyacrylamide gel in TBE buffer 
(0.4 mol/L Tris, 0.45 mol/L boric acid, 0.5 mol/L EDTA, 
pH 8.0). After electrophoresis, the gel was dried and 
autoradiographed by exposure to X-ray film for 24 h.
Gene silencing
2 × 105 cells were transfected with 400 nmol/L 
of 20–25 nucleotide non targeting scrambled siRNA 
(Control siRNA-A, Santa Cruz Biotechnology Inc.) or 
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specific siRNA pools for CAXII, CAIX or HIF-1α (Santa 
Cruz Biotechnology Inc.), following the manufacturer’s 
instructions. To verify the silencing efficacy, 24 h after the 
transfection the levels of mRNAs were checked by qRT-
PCR, 48 h after the transfection the expression of proteins 
was checked by Western blotting. To verify the absence of 
cell toxicity after silencing, cell proliferation, apoptosis 
and viability was measured, as reported below.
Cell proliferation, apoptosis and senescence
To evaluate cell proliferation, 5 × 105 cells were 
grown on sterile glass coverslips, rinsed and fixed with 4% 
w/v paraformaldehyde for 15 min, then permeabilized with 
0.1% v/v Triton-X100 for 5 min on ice, washed three times 
with PBS and stained with an anti-Ki67 antibody (Abcam) 
for 1 h at room temperature. After washing, samples were 
incubated with an AlexaFluor 488-conjugated secondary 
antibody (Millipore) for 1 h and re-washed. Finally, cells 
were stained with PI (1 μg/ml) to counterstain the nuclei, 
and washed again. The coverslips were mounted with 
4 μL of Gel Mount Aqueous Mounting and examined by 
confocal microscopy as detailed above. Early and late 
apoptosis was measured by the Annexin V/Propidium 
Iodide Apoptosis Detection Kit (Sigma Chemical Co.). 
1 × 105 cells were analyzed with a FACS-Calibur flow 
cytometer (Becton Dickinson). The percentage of cells 
positive to annexin V-FITC and PI was calculated with the 
Cell Quest software (Becton Dickinson). Cell senescence 
was evaluated on 5 × 105 cells fixed and stained with the 
Senescence Cells Histochemical Staining Kit (Sigma 
Chemical Co.), following the manufacturer’s instruction. 
Samples were examined with a Leica DC100 fluorescence 
microscope (Leica Microsystems GmbH, Wetzlar, 
Germany). For each experimental point, a minimum of 
five microscopic fields were examined.
Intracellular doxorubicin accumulation
Doxorubicin content was measured fluorimetrically 
as detailed elsewhere [55]. The results were expressed as 
nmol doxorubicin/mg cell proteins, according to a titration 
curve previously set.
Cell viability
Cell viability was evaluated by measuring the 
percentage of cells stained with neutral red dye, as 
reported previously [49]. The viability of untreated cells 
was considered 100%; the results were expressed as 
percentage of viable cells in each experimental condition 
versus untreated cells.
ATPase Pgp activity
The assay was performed on Pgp-enriched 
membrane vesicles as detailed elsewhere [56]. Verapamil 
(10 μmol/L) was added to the reaction mix to achieve a 
maximal activation of the Pgp ATPase activity. Results 
were expressed as nmol hydrolyzed phosphate (Pi)/min/
mg proteins, according to the titration curve previously 
prepared.
Intracellular pH (pHi) measurement
The pHi was measured by incubating whole cells 
with 5 μmol/L of 2’,7’-bis-(2-carboxyethyl)-5-(and-6)-
carboxyfluorescein acetoxymethyl ester (BCECF-AM) for 
15 min at 37°C and reading the intracellular fluorescence 
by a FACSCalibur flow cytometer (Becton Dickinson). 
The intracellular fluorescence was converted into pH units 
according to a titration curve, as described previously [41].
Statistical analysis
All data in text and figures are provided as means ± 
SD. The results were analyzed by a one-way Analysis of 
Variance (ANOVA). A p < 0.05 was considered significant.
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SUPPLEMENTARY FIGURES AND TABLES
Supplementary Figure 1: CAXII topology. The topology of CAXII was obtained with Protter software (Omasits U, Ahrens CH, 
Müller S, Wollscheid B. Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics 
2014; 30: 884–886; http://wlab.ethz.ch/protter).
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2014
Supplementary Figure 2: Glycosylated versus deglycosylated Pgp and MRP1 in chemoresistant colon cancer cells.  
(A) Biotinylated plasma membrane extracts from human chemoresistant colon cancer HT29/dx cells were analyzed by Western blotting for 
the expression of Pgp and MRP1, with antibodies recognizing the glycosylated (i.e. 170 kDa band for Pgp, 190 kDa band for MRP1) and the 
deglycosylated (i.e. 150 kDa band for Pgp, 98 kDa band for MRP1) form of each protein. As internal control, extracts were incubated 1 h at 
37°C with 1 μU of recombinant peptide-N-glycosidase F (PNGase F), to remove N-glycosylation. The pan-cadherin expression was used 
as a control of equal protein loading. The figure is representative of three experiments with similar results. (B) The densitometric analysis 
between glycosylated and deglycosylated bands (glyc/deglyc ratio) was performed with the ImageJ software (http://imagej.nih.gov/ij/).
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Supplementary Figure 3: Expression of CAXII in different human tissues. The expression level of CAXII was analyzed 
with the BioGPS tool (http://biogps.org, http://genomebiology.com/2009/10/11/R130), GeneAtlas U133A (http://www.ncbi.nlm.nih.gov/
pubmed/15075390), gcrma, probe 203963_at. The relative expression level of CAXII in colon adenocarcinoma is indicated.
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2014
Supplementary Figure 4: Expression of Pgp in different human tissues. The expression level of Pgp was analyzed with 
the BioGPS tool (http://biogps.org, http://genomebiology.com/2009/10/11/R130), GeneAtlas U133A (http://www.ncbi.nlm.nih.gov/
pubmed/15075390), gcrma, probe 209993_at. The relative expression level of Pgp in colon adenocarcinoma is indicated.
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Supplementary Figure 4: Expression of Pgp in different human tissues. The expression level of Pgp was analyzed with 
the BioGPS tool (http://biogps.org, http://genomebiology.com/2009/10/11/R130), GeneAtlas U133A (http://www.ncbi.nlm.nih.gov/
pubmed/15075390), gcrma, probe 209993_at. The relative expression level of Pgp in colon adenocarcinoma is indicated.
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Supplementary Figure 5: Expression of MRP1 in different human tissues. The expression level of MRP1 was analyzed 
with the BioGPS tool (http://biogps.org, http://genomebiology.com/2009/10/11/R130), GeneAtlas U133A (http://www.ncbi.nlm.nih.gov/
pubmed/15075390), gcrma, probe 202804_at. The relative expression level of MRP1 in colon adenocarcinoma is indicated.
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Supplementary Figure 6: Expression of HIF-1α target genes in chemosensitive and chemoresistant colon cancer 
cells. The mRNA level of glucose transporter 1 (GLUT1), hexokinase (HK), aldolase-A (ALDO-A), glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), phosphoglycerate kinase (PGK), enolase-A (ENO-A), lactate dehydrogenase (LDH), vascular endothelial growth 
factor (VEGF), erythropoietin (EPO) was detected by qRT-PCR in normoxic HT29 and HT29/dx cells. As positive control of HIF-1α 
activation, the expression of the same mRNAs was measured in HT29 cultured in hypoxic conditions (2% O2 for 24 h; HYP). Data are 
presented as means ± SD (n = 4). For all panels, versus normoxic HT29: * p < 0.001.
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Supplementary Figure 7: CAXII is associated with both glycosylated and deglycosylated Pgp. (A) Biotinylated plasma 
membrane extracts from human chemoresistant colon cancer HT29/dx cells were incubated 1 h at 37°C with (+) or without (−) 1 μU of 
PNGase F, immunoprecipitated (IP) with an anti-Pgp antibody recognizing both the glycosylated and the deglycosylated form of Pgp, 
then immunoblotted (IB) with an anti-CAXII or an anti-Pgp antibody. No Ab: samples immunoprecipitated without antibody. The figure is 
representative of two experiments with similar results. (B) Pgp ATPase activity was measured spectrophotometrically on Pgp-rich vesicles 
extracted from membrane fractions, pre-treated or not with PNGase F as reported in A. Data are presented as means ± SD (n = 3).
Supplementary Figure 8: CAXII silencing in lung and osteosarcoma chemoresistant cells. Human chemoresistant lung 
cancer A549/dx cells and osteosarcoma U2-OS/dx580 cells were cultured for 48 h with fresh medium (CTRL), treated with a non targeting 
scrambled siRNA (scr) or with a CAXII-targeting specific siRNA pool (siCAXII). Chemosensitive A549 and U2-OS cells were included as 
control. The expression of CAXII was measured in whole cell lysates by Western blotting. The β-tubulin expression was used as a control 
of equal protein loading. The figure is representative of two experiments with similar results.
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Supplementary Figure 9: Pgp topology. The topology of Pgp was obtained with Protter software (Omasits U, Ahrens CH, Müller 
S, Wollscheid B. Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics 2014; 
30: 884–886; http://wlab.ethz.ch/protter).
Supplemental Table 1. Quantitative analysis of glycoproteins present on HT29 and HT29/dx cells surface 
 
Acces 
sion UP symbol Gene name CD 
Peptide 
counted 
Peptide  
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quantitation 
Normalized 
abundance  
HT29/dx  
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Normalized 
abundance 
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untreated 
Log2 ratio DX/HT29 
untretaed Surfaceome 
Phobius 
TM Description 
            
O15460 P4HA2_HUMAN P4HA2   1 1 9.98E+00 3.33E+04 -11.704   0 Prolyl 4-hydroxylase subunit alpha-2 
P08571 CD14_HUMAN CD14 CD14 1 1 9.98E+00 2.04E+04 -10.997   GPI Monocyte differentiation antigen CD14 
Q92876 KLK6_HUMAN KLK6   1 1 9.98E+00 1.22E+04 -10.261   0 Kallikrein-6 
O95302 FKBP9_HUMAN FKBP9   3 3 8.10E+02 1.16E+05 -7.160   0 Peptidyl-prolyl cis-trans isomerase FKBP9 
Q9UNN8 EPCR_HUMAN PROCR CD201 2 1 2.61E+02 2.74E+04 -6.717 Y 1 Endothelial protein C receptor 
O60512 B4GT3_HUMAN B4GALT3   1 1 6.95E+02 6.59E+04 -6.566   0 Beta-1,4-galactosyltransferase 3 
P30533 AMRP_HUMAN LRPAP1   1 1 8.72E+02 7.07E+04 -6.343   0 Alpha-2-macroglobulin receptor-associated protein 
P55082 MFAP3_HUMAN MFAP3   1 1 1.04E+02 7.74E+03 -6.213   1 Microfibril-associated glycoprotein 3 
P04066 FUCO_HUMAN FUCA1   1 1 7.95E+01 2.69E+03 -5.083   0 Tissue alpha-L-fucosidase 
Q5PT55 NTCP5_HUMAN SLC10A5   1 1 9.87E+01 3.15E+03 -4.997 Y 9 Sodium\bile acid cotransporter 5 
P18084 ITB5_HUMAN ITGB5   1 1 2.38E+03 7.14E+04 -4.909 Y 1 Integrin beta-5 
O60704 TPST2_HUMAN TPST2   1 1 7.03E+02 1.87E+04 -4.731   0 Protein-tyrosine sulfotransferase 2 
P30825 CTR1_HUMAN SLC7A1   7 7 2.73E+05 6.28E+06 -4.526 Y 14 High affinity cationic amino acid transporter 1 
Q9H6Y7 RN167_HUMAN RNF167   2 2 2.58E+03 5.43E+04 -4.395 Y 1 E3 ubiquitin-protein ligase RNF167 
P55268 LAMB2_HUMAN LAMB2   1 1 2.00E+03 4.20E+04 -4.392   0 Laminin subunit beta-2 
Q14435 GALT3_HUMAN GALNT3   2 2 2.03E+03 3.52E+04 -4.118   1 Polypeptide N-acetylgalactosaminyltransferase 3 
P54851 EMP2_HUMAN EMP2   1 1 8.79E+03 1.44E+05 -4.029 Y 3 Epithelial membrane protein 2 
P55058 PLTP_HUMAN PLTP   3 3 2.99E+03 4.72E+04 -3.984   0 Phospholipid transfer protein 
Q09327 
MGAT3_HUMA
N MGAT3   2 2 2.96E+03 4.57E+04 -3.948   0 Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase 
Q13443 
ADAM9_HUMA
N ADAM9   2 2 5.72E+03 8.02E+04 -3.809 Y 1 Disintegrin and metalloproteinase domain-containing protein 9 
O43852 CALU_HUMAN CALU   1 1 4.11E+04 5.73E+05 -3.799   0 Calumenin 
P54852 EMP3_HUMAN EMP3   1 1 2.36E+02 3.23E+03 -3.778 Y 3 Epithelial membrane protein 3 
P30443 1A01_HUMAN HLA-A   3 3 1.11E+04 1.45E+05 -3.707 Y 1 HLA class I histocompatibility antigen, A-1 alpha chain 
Q9UQV4 LAMP3_HUMAN LAMP3 CD208 1 1 5.73E+03 7.40E+04 -3.692   1 Lysosome-associated membrane glycoprotein 3 
Q10589 BST2_HUMAN BST2 CD317 9 9 3.87E+05 4.69E+06 -3.599   1, GPI Bone marrow stromal antigen 2 
P09958 FURIN_HUMAN FURIN   2 2 1.27E+04 1.44E+05 -3.505   1 Furin 
Q9C0K1 S39A8_HUMAN SLC39A8   2 2 9.69E+03 1.05E+05 -3.431 Y 6 Zinc transporter ZIP8 
P30685 1B35_HUMAN HLA-B   2 2 1.23E+04 1.32E+05 -3.426 Y 1 HLA class I histocompatibility antigen, B-35 alpha chain 
O96005 CLPT1_HUMAN CLPTM1   3 3 8.05E+04 8.08E+05 -3.327 Y 5 Cleft lip and palate transmembrane protein 1 
P02786 TFR1_HUMAN TFRC CD71 1 1 3.12E+04 2.85E+05 -3.191 Y 1, GPI Transferrin receptor protein 1 
Q96T83 SL9A7_HUMAN SLC9A7   2 2 2.48E+04 2.21E+05 -3.155   13 Sodium\hydrogen exchanger 7 
P04439 1A03_HUMAN HLA-A   1 1 2.56E+03 2.23E+04 -3.125 Y 1 HLA class I histocompatibility antigen, A-3 alpha chain 
Q9Y666 S12A7_HUMAN SLC12A7   3 3 8.78E+04 7.40E+05 -3.076 Y 12 Solute carrier family 12 member 7 
Q9NRB3 
CHSTC_HUMA
N CHST12   3 3 1.91E+04 1.56E+05 -3.032   1 Carbohydrate sulfotransferase 12 
Q96G97 BSCL2_HUMAN BSCL2   2 2 3.38E+04 2.61E+05 -2.949   3 Seipin 
P57057 GLPT_HUMAN SLC37A1   2 2 1.95E+04 1.49E+05 -2.936 Y 12 Glycerol-3-phosphate transporter 
Q8NHS3 MFSD8_HUMAN MFSD8   1 1 2.36E+04 1.64E+05 -2.800 Y 12 Major facilitator superfamily domain-containing protein 8 
Q9UQ53 
MGT4B_HUMA
N MGAT4B   1 1 1.38E+05 9.52E+05 -2.782   0 Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B 
Q15758 AAAT_HUMAN SLC1A5   8 8 2.47E+06 1.69E+07 -2.772 Y 9 Neutral amino acid transporter B(0) 
Q8IZA0 K319L_HUMAN KIAA0319L   2 2 1.37E+04 9.38E+04 -2.771 Y 2 Uncharacterized protein KIAA0319-like 
Q6YBV0 S36A4_HUMAN SLC36A4   2 2 1.37E+04 9.18E+04 -2.749 Y 10 Proton-coupled amino acid transporter 4 
P09758 TACD2_HUMAN TACSTD2   3 3 2.63E+04 1.73E+05 -2.723 Y 1 Tumor-associated calcium signal transducer 2 
P11117 PPAL_HUMAN ACP2   3 3 1.21E+04 7.90E+04 -2.700   1 Lysosomal acid phosphatase 
O60449 LY75_HUMAN LY75 CD205 4 4 1.08E+05 6.93E+05 -2.677 Y 1 Lymphocyte antigen 75 
O43567 RNF13_HUMAN RNF13   1 1 6.28E+03 4.01E+04 -2.676   1 RING finger protein 13 
Q6ZRP7 
QSOX2_HUMA
N QSOX2   3 2 8.43E+04 4.94E+05 -2.551 Y 1 Sulfhydryl oxidase 2 
P04062 GLCM_HUMAN GBA   6 5 1.57E+05 8.65E+05 -2.462   0 Glucosylceramidase 
Q70UQ0 IKIP_HUMAN IKIP   1 1 1.37E+03 7.49E+03 -2.455   1 Inhibitor of nuclear factor kappa-B kinase-interacting protein 
Q5TF39 NAGT1_HUMAN NAGLT1   1 1 1.20E+04 6.53E+04 -2.445   11 Sodium-dependent glucose transporter 1 
P08069 IGF1R_HUMAN IGF1R CD221 5 5 8.17E+04 4.40E+05 -2.430 Y 1 Insulin-like growth factor 1 receptor 
Q9NYU2 
UGGG1_HUMA
N UGGT1   1 1 2.59E+04 1.39E+05 -2.426   1 UDP-glucose:glycoprotein glucosyltransferase 1 
Q5T2D2 TRML2_HUMAN TREML2   1 1 2.36E+03 1.22E+04 -2.368 Y 1 Trem-like transcript 2 protein 
P11279 LAMP1_HUMAN LAMP1 CD107a 26 25 1.02E+06 5.03E+06 -2.305 Y 1 Lysosome-associated membrane glycoprotein 1 
Q7Z2K6 
ERMP1_HUMA
N ERMP1   2 2 1.13E+04 5.43E+04 -2.267 Y 10 Endoplasmic reticulum metallopeptidase 1 
P53794 SC5A3_HUMAN SLC5A3   1 1 8.48E+03 4.08E+04 -2.265   13 Sodium\myo-inositol cotransporter 
Q7Z3C6 ATG9A_HUMAN ATG9A   1 1 2.66E+03 1.25E+04 -2.236 Y 4 Autophagy-related protein 9A 
Q687X5 STEA4_HUMAN STEAP4   1 1 2.06E+04 9.65E+04 -2.230 Y 6 Metalloreductase STEAP4 
Q9Y2E5 MA2B2_HUMAN MAN2B2   1 1 8.40E+03 3.91E+04 -2.217   0 Epididymis-specific alpha-mannosidase 
Q99808 S29A1_HUMAN SLC29A1   3 3 2.76E+05 1.28E+06 -2.211 Y 11 Equilibrative nucleoside transporter 1 
Q11201 SIA4A_HUMAN ST3GAL1   17 17 4.66E+05 2.15E+06 -2.208   0 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 
Q4ZIN3 MBRL_HUMAN C19orf6   1 1 1.12E+04 5.15E+04 -2.199 Y 6 Membralin 
Q16769 QPCT_HUMAN QPCT   1 1 1.09E+04 4.86E+04 -2.157   0 Glutaminyl-peptide cyclotransferase 
P49281 
NRAM2_HUMA
N SLC11A2   1 1 9.26E+04 4.12E+05 -2.154 Y 12 Natural resistance-associated macrophage protein 2 
Q8NBW4 S38A9_HUMAN SLC38A9   1 1 2.20E+03 9.70E+03 -2.139 Y 11 Putative sodium-coupled neutral amino acid transporter 9 
O15438 MRP3_HUMAN ABCC3   2 2 1.37E+04 5.73E+04 -2.065 Y 17 Canalicular multispecific organic anion transporter 2 
P19526 FUT1_HUMAN FUT1   1 1 5.40E+04 2.22E+05 -2.040   0 Galactoside 2-alpha-L-fucosyltransferase 1 
Q9NV96 CC50A_HUMAN TMEM30A   2 2 6.49E+04 2.65E+05 -2.031 Y 2 Cell cycle control protein 50A 
Q8NCR9 CLRN3_HUMAN CLRN3   1 1 3.12E+04 1.27E+05 -2.027 Y 4 Clarin-3 
Q9NXG6 P4HTM_HUMAN P4HTM   1 1 9.17E+03 3.70E+04 -2.014   1 Transmembrane prolyl 4-hydroxylase 
Q9H330 CI005_HUMAN C9orf5   2 2 1.71E+04 6.90E+04 -2.012 Y 16 Transmembrane protein C9orf5 
O75063 FA20B_HUMAN FAM20B   2 2 7.95E+03 3.19E+04 -2.004   0 Protein FAM20B 
P30450 1A26_HUMAN HLA-A   1 1 9.26E+04 3.70E+05 -1.998 Y 1 HLA class I histocompatibility antigen, A-26 alpha chain 
Q9UIQ6 LCAP_HUMAN LNPEP   7 7 3.24E+05 1.25E+06 -1.948 Y 1 Leucyl-cystinyl aminopeptidase 
Q96AY3 FKB10_HUMAN FKBP10   3 3 1.25E+04 4.77E+04 -1.929   0 Peptidyl-prolyl cis-trans isomerase FKBP10 
Q9NQ84 
GPC5C_HUMA
N GPRC5C   1 1 2.81E+04 1.06E+05 -1.920 Y 7 G-protein coupled receptor family C group 5 member C 
A1A5B4 ANO9_HUMAN ANO9   2 2 2.60E+04 9.67E+04 -1.895 Y 8 Anoctamin-9 
Q0P6H9 TMM62_HUMAN TMEM62   2 2 1.47E+04 5.46E+04 -1.893 Y 5 Transmembrane protein 62 
Q9NX62 IMPA3_HUMAN IMPAD1   3 3 2.26E+05 8.17E+05 -1.856   1 Inositol monophosphatase 3 
Q8IV08 PLD3_HUMAN PLD3   2 2 2.10E+05 7.44E+05 -1.826 Y 1 Phospholipase D3 
O94923 GLCE_HUMAN GLCE   1 1 7.46E+03 2.62E+04 -1.811   0 D-glucuronyl C5-epimerase 
Q12913 PTPRJ_HUMAN PTPRJ CD148 6 5 1.06E+05 3.69E+05 -1.803 Y 1 Receptor-type tyrosine-protein phosphatase eta 
P56199 ITA1_HUMAN ITGA1 CD49a 8 8 2.86E+05 9.97E+05 -1.801   1 Integrin alpha-1 
P07339 CATD_HUMAN CTSD   2 2 1.25E+05 4.30E+05 -1.776   0 Cathepsin D 
Q3ZCQ3 F174B_HUMAN FAM174B   1 1 3.76E+05 1.28E+06 -1.766 Y 1 Membrane protein FAM174B 
Q9BXS4 TMM59_HUMAN TMEM59   3 3 8.28E+04 2.76E+05 -1.739 Y 1 Transmembrane protein 59 
O00469 PLOD2_HUMAN PLOD2   2 2 8.39E+03 2.79E+04 -1.735   0 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 
Q5XXA6 ANO1_HUMAN ANO1   2 2 7.09E+03 2.24E+04 -1.663 Y 8 Anoctamin-1 
Q7LGA3 HS2ST_HUMAN HS2ST1   2 2 9.15E+04 2.87E+05 -1.650   0 Heparan sulfate 2-O-sulfotransferase 1 
Q9C0H2 TTYH3_HUMAN TTYH3   2 2 6.84E+04 2.14E+05 -1.644 Y 5 Protein tweety homolog 3 
Q8N0Z9 YL020_HUMAN     3 3 2.62E+04 8.17E+04 -1.642   1 Ig-like domain-containing protein FLJ20674  SV=1 
Q12767 K0195_HUMAN KIAA0195   1 1 8.88E+03 2.69E+04 -1.598 Y 10 Uncharacterized protein KIAA0195 
Q9HBB8 
MUCDL_HUMA
N MUPCDH   4 4 1.51E+05 4.55E+05 -1.594 Y 1 Mucin and cadherin-like protein 
P02749 APOH_HUMAN APOH   1 1 5.48E+03 1.64E+04 -1.582   0 Beta-2-glycoprotein 1 
Q8NBN3 TM87A_HUMAN TMEM87A   9 8 4.57E+06 1.36E+07 -1.570 Y 7 Transmembrane protein 87A 
Q9H2A7 CXL16_HUMAN CXCL16   1 1 7.13E+02 2.11E+03 -1.566 Y 1 C-X-C motif chemokine 16 
P13688 
CEAM1_HUMA
N CEACAM1 CD66a 3 3 1.09E+05 3.20E+05 -1.554 Y 1 Carcinoembryonic antigen-related cell adhesion molecule 1 
Q9NXL6 SIDT1_HUMAN SIDT1   1 1 8.44E+03 2.45E+04 -1.540 Y 11 SID1 transmembrane family member 1 
P07858 CATB_HUMAN CTSB   1 1 4.52E+04 1.31E+05 -1.530   0 Cathepsin B 
P00533 EGFR_HUMAN EGFR   2 2 1.46E+05 4.18E+05 -1.513 Y 1 Epidermal growth factor receptor 
P80188 NGAL_HUMAN LCN2   1 1 7.82E+04 2.21E+05 -1.498   0 Neutrophil gelatinase-associated lipocalin 
O00461 GOLI4_HUMAN GOLIM4   2 2 6.74E+04 1.90E+05 -1.497   1 Golgi integral membrane protein 4 
Q96BQ1 FAM3D_HUMAN FAM3D   2 2 5.00E+04 1.41E+05 -1.494   1 Protein FAM3D 
Q96NT5 PCFT_HUMAN SLC46A1   1 1 3.53E+04 9.85E+04 -1.480 Y 11 Proton-coupled folate transporter 
O75071 K0494_HUMAN KIAA0494   3 3 2.73E+05 7.48E+05 -1.453   1 EF-hand domain-containing protein KIAA0494 
O43291 SPIT2_HUMAN SPINT2   3 3 1.50E+05 4.09E+05 -1.450 Y 1 Kunitz-type protease inhibitor 2 
O15321 TM9S1_HUMAN TM9SF1   1 1 6.29E+04 1.68E+05 -1.419 Y 9 Transmembrane 9 superfamily member 1 
O00468 AGRIN_HUMAN AGRN   5 4 1.69E+05 4.50E+05 -1.419   0 Agrin 
Q9Y5Y6 ST14_HUMAN ST14   4 4 2.46E+05 6.33E+05 -1.366 Y 1 Suppressor of tumorigenicity 14 protein 
Q9Y639 NPTN_HUMAN NPTN   7 7 5.05E+04 1.27E+05 -1.335 Y 1 Neuroplastin 
Q6EMK4 VASN_HUMAN VASN   1 1 9.59E+02 2.42E+03 -1.334 Y 1 Vasorin 
Q14108 SCRB2_HUMAN SCARB2   18 17 7.53E+06 1.89E+07 -1.330 Y 1 Lysosome membrane protein 2 
Q8N697 S15A4_HUMAN SLC15A4   3 3 1.70E+05 4.28E+05 -1.326 Y 13 Solute carrier family 15 member 4 
Q99523 SORT_HUMAN SORT1   3 3 1.83E+05 4.59E+05 -1.325   1 Sortilin 
Q93050 VPP1_HUMAN ATP6V0A1   1 1 7.08E+04 1.76E+05 -1.310 Y 8 V-type proton ATPase 116 kDa subunit a isoform 1 
Q8NBJ4 
GOLM1_HUMA
N GOLM1   2 2 1.51E+06 3.72E+06 -1.305   0 Golgi membrane protein 1 
Q9HAS3 S28A3_HUMAN SLC28A3   1 1 1.13E+04 2.78E+04 -1.302 Y 13 Solute carrier family 28 member 3 
Q9NZP8 C1RL_HUMAN C1RL   1 1 8.26E+03 2.02E+04 -1.291   0 Complement C1r subcomponent-like protein 
P21589 5NTD_HUMAN NT5E CD73 3 3 2.32E+05 5.53E+05 -1.253 Y 1, GPI 5'-nucleotidase 
Q6P4E1 CASC4_HUMAN CASC4   4 4 3.18E+04 7.54E+04 -1.247   1 Protein CASC4 
Q9NUN5 LMBD1_HUMAN LMBRD1   9 9 7.56E+05 1.78E+06 -1.237 Y 9 Probable lysosomal cobalamin transporter 
P49641 MA2A2_HUMAN MAN2A2   2 2 2.18E+04 5.08E+04 -1.218   1 Alpha-mannosidase 2x 
Q11206 SIA4C_HUMAN ST3GAL4   8 8 5.37E+05 1.24E+06 -1.211   0 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 
Q08380 LG3BP_HUMAN LGALS3BP   17 17 1.49E+07 3.44E+07 -1.211   0 Galectin-3-binding protein 
P42892 ECE1_HUMAN ECE1   19 19 6.51E+05 1.50E+06 -1.200 Y 1 Endothelin-converting enzyme 1 
Q13586 STIM1_HUMAN STIM1   4 4 2.92E+05 6.64E+05 -1.184 Y 1 Stromal interaction molecule 1 
Q16563 SYPL1_HUMAN SYPL1   2 2 8.80E+04 1.99E+05 -1.180 Y 3 Synaptophysin-like protein 1 
Q04900 MUC24_HUMAN CD164 CD164 2 2 2.25E+04 5.08E+04 -1.176 Y 0 Sialomucin core protein 24 
P43307 SSRA_HUMAN SSR1   3 3 2.54E+04 5.72E+04 -1.171   1 Translocon-associated protein subunit alpha 
Q7Z6M3 MCA32_HUMAN MCA32   1 1 1.65E+04 3.68E+04 -1.160   1 Probable mast cell antigen 32 homolog 
Q8TEM1 PO210_HUMAN NUP210   5 5 2.36E+05 5.25E+05 -1.151   1 Nuclear pore membrane glycoprotein 210 
Q4KMQ2 ANO6_HUMAN ANO6   3 3 9.77E+04 2.15E+05 -1.135 Y 8 Anoctamin-6 
P14625 ENPL_HUMAN HSP90B1   5 5 9.77E+05 2.12E+06 -1.121   0 Endoplasmin 
Q13510 ASAH1_HUMAN ASAH1   1 1 1.04E+04 2.25E+04 -1.119   0 Acid ceramidase 
Q8WWB7 
NCUG1_HUMA
N C1orf85   5 5 2.50E+05 5.34E+05 -1.095 Y 1 Lysosomal protein NCU-G1 
Q7Z4H8 KDEL2_HUMAN KDELC2   3 3 4.44E+04 9.47E+04 -1.092   0 KDEL motif-containing protein 2 
Q68CQ7 GL8D1_HUMAN GLT8D1   3 3 1.27E+05 2.67E+05 -1.070   0 Glycosyltransferase 8 domain-containing protein 1 
Q06481 APLP2_HUMAN APLP2   2 2 1.01E+05 2.13E+05 -1.070   1 Amyloid-like protein 2 
Q86YB8 ERO1B_HUMAN ERO1LB   1 1 9.23E+04 1.92E+05 -1.055   0 ERO1-like protein beta 
Q8NBK3 SUMF1_HUMAN SUMF1   1 1 2.38E+04 4.92E+04 -1.048   0 Sulfatase-modifying factor 1 
Q969N2 PIGT_HUMAN PIGT   1 1 9.22E+03 1.89E+04 -1.038   1 GPI transamidase component PIG-T 
Q8N6G5 CGAT2_HUMAN 
CSGALNACT
2   1 1 1.40E+04 2.87E+04 -1.031   1 Chondroitin sulfate N-acetylgalactosaminyltransferase 2 
O00299 CLIC1_HUMAN CLIC1   1 1 1.75E+04 3.55E+04 -1.025   0 Chloride intracellular channel protein 1 
Q96G23 LASS2_HUMAN LASS2   2 2 5.19E+04 1.06E+05 -1.023   6 LAG1 longevity assurance homolog 2 
Q9Y653 GPR56_HUMAN GPR56   4 3 6.65E+04 1.34E+05 -1.009 Y 7 G-protein coupled receptor 56 
O95477 ABCA1_HUMAN ABCA1   4 4 3.48E+04 6.70E+04 -0.943 Y 14 ATP-binding cassette sub-family A member 1 
O15230 LAMA5_HUMAN LAMA5   3 3 7.36E+04 1.40E+05 -0.931   0 Laminin subunit alpha-5 
Q9NPC4 A4GAT_HUMAN A4GALT   2 2 1.36E+05 2.59E+05 -0.928   1 Lactosylceramide 4-alpha-galactosyltransferase 
Q16706 MA2A1_HUMAN MAN2A1   2 2 6.16E+05 1.17E+06 -0.922   1 Alpha-mannosidase 2 
O75976 CBPD_HUMAN CPD   16 15 2.41E+06 4.49E+06 -0.895 Y 1, GPI Carboxypeptidase D 
O95857 TSN13_HUMAN TSPAN13   6 6 3.11E+05 5.72E+05 -0.879 Y 4 Tetraspanin-13 
Q9BZM5 N2DL2_HUMAN ULBP2   4 4 3.96E+04 7.27E+04 -0.876 Y 1, GPI NKG2D ligand 2 
Q9NYU1 
UGGG2_HUMA
N UGGT2   1 1 3.02E+03 5.55E+03 -0.875   0 UDP-glucose:glycoprotein glucosyltransferase 2 
Q96J42 TXD15_HUMAN TXNDC15   3 2 7.18E+04 1.31E+05 -0.870 Y 1 Thioredoxin domain-containing protein 15 
Q3T906 
GNPTA_HUMA
N GNPTAB   8 8 4.87E+05 8.85E+05 -0.863   2 N-acetylglucosamine-1-phosphotransferase subunits alpha\beta 
O95395 GCNT3_HUMAN GCNT3   4 3 9.01E+04 1.62E+05 -0.850   1 
Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-
acetylglucosaminyltransferase 3 
P05026 AT1B1_HUMAN ATP1B1   14 14 3.74E+06 6.74E+06 -0.848 Y 1 Sodium\potassium-transporting ATPase subunit beta-1 
Q08431 MFGM_HUMAN MFGE8   4 4 1.13E+05 2.03E+05 -0.844   0 Lactadherin 
Q9H813 TM206_HUMAN TMEM206   1 1 8.26E+04 1.46E+05 -0.827 Y 2 Transmembrane protein 206 
Q5VW38 GP107_HUMAN GPR107   6 6 2.72E+06 4.82E+06 -0.825 Y 7 Protein GPR107 
Q9NXH8 CI167_HUMAN C9orf167   1 1 8.35E+04 1.48E+05 -0.824   1 Torsin family protein C9orf167 
Q9NQZ7 ENTP7_HUMAN ENTPD7   1 1 5.32E+04 9.39E+04 -0.819 Y 2 Ectonucleoside triphosphate diphosphohydrolase 7 
Q9NRX5 SERC1_HUMAN SERINC1   3 3 1.13E+06 1.97E+06 -0.799 Y 10 Serine incorporator 1 
Q8NBJ5 GT251_HUMAN GLT25D1   4 4 4.13E+04 7.18E+04 -0.797   0 Procollagen galactosyltransferase 1 
Q92673 SORL_HUMAN SORL1   7 7 1.59E+05 2.76E+05 -0.794 Y 1 Sortilin-related receptor 
Q9BZC7 ABCA2_HUMAN ABCA2   1 1 4.45E+04 7.70E+04 -0.792 Y 14 ATP-binding cassette sub-family A member 2 
P20645 MPRD_HUMAN M6PR   6 6 1.13E+06 1.95E+06 -0.791 Y 1 Cation-dependent mannose-6-phosphate receptor 
P43007 SATT_HUMAN SLC1A4   1 1 1.65E+04 2.85E+04 -0.790 Y 9 Neutral amino acid transporter A 
Q6NSJ0 K1161_HUMAN KIAA1161   3 3 2.62E+04 4.52E+04 -0.784 Y 1 Uncharacterized family 31 glucosidase KIAA1161 
Q9BXP2 S12A9_HUMAN SLC12A9   3 3 4.93E+04 8.43E+04 -0.773 Y 13 Solute carrier family 12 member 9 
P04844 RPN2_HUMAN RPN2   2 2 4.26E+04 7.19E+04 -0.754 Y 3 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 
P10253 LYAG_HUMAN GAA   3 3 2.35E+05 3.87E+05 -0.719   1 Lysosomal alpha-glucosidase 
Q9NY97 B3GN2_HUMAN B3GNT2   6 6 7.51E+05 1.23E+06 -0.711   1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 
P30989 NTR1_HUMAN NTSR1   5 5 9.55E+05 1.55E+06 -0.697 Y 7,GPI Neurotensin receptor type 1 
Q12907 LMAN2_HUMAN LMAN2   4 4 3.63E+05 5.84E+05 -0.688   1 Vesicular integral-membrane protein VIP36 
P50895 BCAM_HUMAN BCAM CD239 1 1 1.91E+05 3.07E+05 -0.684   1 Basal cell adhesion molecule 
Q8IWA5 CTL2_HUMAN SLC44A2   6 5 1.64E+06 2.62E+06 -0.677 Y 10 Choline transporter-like protein 2 
Q5ZPR3 CD276_HUMAN CD276 CD276 4 4 3.24E+05 5.17E+05 -0.673 Y 1 CD276 antigen 
P48029 SC6A8_HUMAN SLC6A8   1 1 7.39E+04 1.18E+05 -0.671 Y 12 Sodium- and chloride-dependent creatine transporter 1 
P78536 ADA17_HUMAN ADAM17 CD156b 2 2 1.95E+04 3.09E+04 -0.666 Y 1 Disintegrin and metalloproteinase domain-containing protein 17 
P35613 BASI_HUMAN BSG CD147 7 7 1.35E+06 2.14E+06 -0.662 Y 1 Basigin 
P10586 PTPRF_HUMAN PTPRF   5 4 1.38E+05 2.18E+05 -0.660 Y 1 Receptor-type tyrosine-protein phosphatase F 
P07686 HEXB_HUMAN HEXB   2 2 1.07E+05 1.68E+05 -0.657   0 Beta-hexosaminidase subunit beta 
P17301 ITA2_HUMAN ITGA2 CD49b 13 13 9.08E+05 1.43E+06 -0.654 Y 1 Integrin alpha-2 
Q6P179 ERAP2_HUMAN ERAP2   3 3 1.65E+05 2.59E+05 -0.645   0 Endoplasmic reticulum aminopeptidase 2 
Q9UHW9 S12A6_HUMAN SLC12A6   2 2 1.07E+03 1.62E+03 -0.597 Y 14 Solute carrier family 12 member 6 
Q8TCJ2 STT3B_HUMAN STT3B   14 14 6.99E+05 1.05E+06 -0.588 Y 13 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3B 
P98160 PGBM_HUMAN HSPG2   2 2 1.33E+05 1.98E+05 -0.580   0 Basement membrane-specific heparan sulfate proteoglycan core protein 
O14657 TOR1B_HUMAN TOR1B   2 1 2.08E+03 3.07E+03 -0.559   0 Torsin-1B 
Q99538 LGMN_HUMAN LGMN   1 1 1.63E+04 2.40E+04 -0.559   0 Legumain 
Q93008 USP9X_HUMAN USP9X   1 1 3.70E+04 5.43E+04 -0.555   0 Probable ubiquitin carboxyl-terminal hydrolase FAF-X 
Q96KA5 CLP1L_HUMAN CLPTM1L   2 2 6.59E+04 9.66E+04 -0.552 Y 6 Cleft lip and palate transmembrane protein 1-like protein 
Q96HA4 CA159_HUMAN C1orf159   1 1 2.20E+04 3.19E+04 -0.540   1 Uncharacterized protein C1orf159 
P54709 AT1B3_HUMAN ATP1B3 CD298 5 5 1.54E+06 2.24E+06 -0.539 Y 1 Sodium\potassium-transporting ATPase subunit beta-3 
Q16880 CGT_HUMAN UGT8   2 2 1.09E+05 1.57E+05 -0.519   1 2-hydroxyacylsphingosine 1-beta-galactosyltransferase 
P11047 LAMC1_HUMAN LAMC1   2 2 4.27E+04 6.11E+04 -0.517   0 Laminin subunit gamma-1 
Q9Y2A9 B3GN3_HUMAN B3GNT3   1 1 4.70E+03 6.62E+03 -0.496   0 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 
P41440 S19A1_HUMAN SLC19A1   1 1 7.32E+04 1.03E+05 -0.496 Y 11 Folate transporter 1 
O75509 TNR21_HUMAN TNFRSF21   2 2 1.16E+05 1.63E+05 -0.492 Y 1 Tumor necrosis factor receptor superfamily member 21 
Q92542 NICA_HUMAN NCSTN   2 2 3.06E+04 4.30E+04 -0.492 Y 1 Nicastrin 
P05556 ITB1_HUMAN ITGB1 CD29 3 3 1.97E+05 2.69E+05 -0.447 Y 1 Integrin beta-1 
P98172 EFNB1_HUMAN EFNB1   3 2 5.82E+04 7.93E+04 -0.446 Y 1 Ephrin-B1 
P02790 HEMO_HUMAN HPX   1 1 3.35E+04 4.56E+04 -0.445   0 Hemopexin 
Q96HE7 ERO1A_HUMAN ERO1L   2 2 7.17E+04 9.73E+04 -0.441   0 ERO1-like protein alpha 
P08962 CD63_HUMAN CD63 CD63 2 2 9.60E+04 1.30E+05 -0.438 Y 4 CD63 antigen 
P04843 RPN1_HUMAN RPN1   2 2 2.59E+04 3.51E+04 -0.435   1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 
Q96AQ6 PBIP1_HUMAN PBXIP1   1 1 3.42E+04 4.62E+04 -0.432   1 Pre-B-cell leukemia transcription factor-interacting protein 1 
P11717 MPRI_HUMAN IGF2R CD222 7 6 4.81E+05 6.45E+05 -0.422 Y 1 Cation-independent mannose-6-phosphate receptor 
Q8TBP5 F174A_HUMAN FAM174A   2 2 5.42E+05 7.24E+05 -0.416 Y 1 Membrane protein FAM174A 
Q9BZR6 RTN4R_HUMAN RTN4R   1 1 8.45E+03 1.11E+04 -0.398   GPI Reticulon-4 receptor 
Q14517 FAT1_HUMAN FAT1   9 9 1.50E+06 1.97E+06 -0.390   1 Protocadherin Fat 1 
Q9UH99 UN84B_HUMAN UNC84B   1 1 2.02E+05 2.63E+05 -0.384   3 Protein unc-84 homolog B 
Q9BU23 LMF2_HUMAN LMF2   2 2 1.78E+04 2.32E+04 -0.383 Y 11 Lipase maturation factor 2 
Q9UHG3 
PCYOX_HUMA
N PCYOX1   3 3 4.10E+04 5.25E+04 -0.356   0 Prenylcysteine oxidase 1 
P46977 STT3A_HUMAN STT3A   9 8 7.35E+05 9.35E+05 -0.347 Y 13 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3A 
P15151 PVR_HUMAN PVR CD155 3 3 9.61E+04 1.21E+05 -0.332 Y 1 Poliovirus receptor 
P30447 1A23_HUMAN HLA-A   3 3 6.00E+04 7.41E+04 -0.306 Y 1 HLA class I histocompatibility antigen, A-23 alpha chain 
Q8NE01 
CNNM3_HUMA
N CNNM3   1 1 6.96E+03 8.51E+03 -0.290   3 Metal transporter CNNM3 
Q86SQ4 GP126_HUMAN GPR126   7 7 2.66E+05 3.22E+05 -0.273 Y 7 G-protein coupled receptor 126 
Q9H2H9 S38A1_HUMAN SLC38A1   1 1 1.92E+06 2.30E+06 -0.260 Y 11 Sodium-coupled neutral amino acid transporter 1 
Q9UIW2 PLXA1_HUMAN PLXNA1   1 1 4.95E+04 5.89E+04 -0.252 Y 1 Plexin-A1 
P54760 EPHB4_HUMAN EPHB4   5 5 2.80E+05 3.33E+05 -0.251 Y 1 Ephrin type-B receptor 4 
Q6P4Q7 
CNNM4_HUMA
N CNNM4   3 3 1.72E+05 2.03E+05 -0.239 Y 4 Metal transporter CNNM4 
Q9NY35 CLDN1_HUMAN CLDND1   2 2 2.21E+04 2.59E+04 -0.229 Y 3 Claudin domain-containing protein 1 
Q86SR1 GLT10_HUMAN GALNT10   1 1 1.05E+04 1.22E+04 -0.214   0 Polypeptide N-acetylgalactosaminyltransferase 10 
P04156 PRIO_HUMAN PRNP CD230 1 1 1.13E+06 1.31E+06 -0.212 Y 2,GPI Major prion protein 
Q9P2C4 TM181_HUMAN TMEM181   6 6 4.68E+05 5.38E+05 -0.201   8 Transmembrane protein 181 
P22607 FGFR3_HUMAN FGFR3 CD333 1 1 1.14E+04 1.29E+04 -0.182 Y 1 Fibroblast growth factor receptor 3 
O95297 MPZL1_HUMAN MPZL1   1 1 4.65E+05 5.27E+05 -0.180 Y 1 Myelin protein zero-like protein 1 
P43251 BTD_HUMAN BTD   2 2 1.04E+05 1.18E+05 -0.178   0 Biotinidase 
Q8N766 K0090_HUMAN KIAA0090   1 1 2.50E+05 2.83E+05 -0.174   1 Uncharacterized protein KIAA0090 
P48723 HSP13_HUMAN HSPA13   1 1 3.92E+04 4.40E+04 -0.164   0 Heat shock 70 kDa protein 13 
Q15223 PVRL1_HUMAN PVRL1 CD111 4 4 3.46E+05 3.87E+05 -0.162 Y 1 Poliovirus receptor-related protein 1 
P15586 GNS_HUMAN GNS   2 1 1.91E+04 2.13E+04 -0.158   0 N-acetylglucosamine-6-sulfatase 
Q9H015 S22A4_HUMAN SLC22A4   2 2 6.06E+04 6.75E+04 -0.156 Y 12 Solute carrier family 22 member 4 
O60568 PLOD3_HUMAN PLOD3   3 3 1.30E+05 1.43E+05 -0.137   0 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 
P08195 4F2_HUMAN SLC3A2 CD98 21 21 2.15E+07 2.34E+07 -0.124 Y 1 4F2 cell-surface antigen heavy chain 
O15533 TPSN_HUMAN TAPBP   1 1 1.97E+04 2.14E+04 -0.120   1 Tapasin 
P08581 MET_HUMAN MET   3 3 3.42E+05 3.68E+05 -0.103 Y 1 Hepatocyte growth factor receptor 
Q9NPR2 SEM4B_HUMAN SEMA4B   6 6 4.39E+05 4.70E+05 -0.100 Y 1 Semaphorin-4B 
Q96AE7 TTC17_HUMAN TTC17   1 1 1.40E+04 1.48E+04 -0.084   0 Tetratricopeptide repeat protein 17 
Q15904 VAS1_HUMAN ATP6AP1   8 8 4.57E+05 4.85E+05 -0.083 Y 1 V-type proton ATPase subunit S1 
P29317 EPHA2_HUMAN EPHA2   5 5 1.96E+06 2.07E+06 -0.079 Y 1 Ephrin type-A receptor 2 
Q12891 HYAL2_HUMAN HYAL2   1 1 2.18E+04 2.30E+04 -0.079   GPI Hyaluronidase-2 
Q96S52 PIGS_HUMAN PIGS   1 1 9.36E+04 9.74E+04 -0.058   2 GPI transamidase component PIG-S 
Q9UBV2 SE1L1_HUMAN SEL1L   4 4 4.69E+05 4.84E+05 -0.046 Y 1 Protein sel-1 homolog 1 
Q92896 GSLG1_HUMAN GLG1   4 4 1.20E+06 1.24E+06 -0.044   1 Golgi apparatus protein 1 
P51788 CLCN2_HUMAN CLCN2   1 1 1.16E+05 1.19E+05 -0.037 Y 12 Chloride channel protein 2 
O15393 TMPS2_HUMAN TMPRSS2   1 1 1.90E+04 1.93E+04 -0.020 Y 1 Transmembrane protease serine 2 
Q9HD43 PTPRH_HUMAN PTPRH   5 5 7.18E+05 7.19E+05 -0.001 Y 1 Receptor-type tyrosine-protein phosphatase H 
Q9UBS9 CA009_HUMAN C1orf9   1 1 1.54E+03 1.54E+03 0.006   1 Protein C1orf9 
Q9HD45 TM9S3_HUMAN TM9SF3   2 2 7.88E+06 7.64E+06 0.044 Y 9 Transmembrane 9 superfamily member 3 
Q9UHN6 
TMEM2_HUMA
N TMEM2   6 5 2.01E+05 1.93E+05 0.055 Y 1 Transmembrane protein 2 
Q04912 RON_HUMAN MST1R CD136 4 3 1.94E+05 1.86E+05 0.056 Y 1 Macrophage-stimulating protein receptor 
Q13433 S39A6_HUMAN SLC39A6   2 2 5.77E+04 5.54E+04 0.057 Y 6 Zinc transporter ZIP6 
Q14573 ITPR3_HUMAN ITPR3   2 2 4.73E+04 4.52E+04 0.065   7 Inositol 1,4,5-trisphosphate receptor type 3 
Q9HAW8 UD110_HUMAN UGT1A10   6 6 8.58E+05 8.15E+05 0.075   1 UDP-glucuronosyltransferase 1-10 
P12259 FA5_HUMAN F5   2 2 5.71E+04 5.42E+04 0.077   0 Coagulation factor V 
Q9UNP4 SIAT9_HUMAN ST3GAL5   1 1 1.48E+04 1.40E+04 0.080 Y 1 Lactosylceramide alpha-2,3-sialyltransferase 
P13473 LAMP2_HUMAN LAMP2 CD107b 6 5 1.73E+05 1.62E+05 0.088 Y 1 Lysosome-associated membrane glycoprotein 2 
P11166 GTR1_HUMAN SLC2A1   4 4 4.92E+06 4.61E+06 0.095 Y 12 Solute carrier family 2, facilitated glucose transporter member 1 
P21583 SCF_HUMAN KITLG   1 1 1.23E+04 1.15E+04 0.103 Y 1 Kit ligand 
Q8N8Z6 DCBD1_HUMAN DCBLD1   1 1 3.17E+04 2.94E+04 0.110 Y 1 Discoidin, CUB and LCCL domain-containing protein 1 
P13987 CD59_HUMAN CD59 CD59 1 1 3.84E+04 3.55E+04 0.116   GPI CD59 glycoprotein 
Q969P0 IGSF8_HUMAN IGSF8 CD316 1 1 9.09E+03 8.26E+03 0.138 Y 1 Immunoglobulin superfamily member 8 
O43688 LPP2_HUMAN PPAP2C   1 1 8.51E+04 7.71E+04 0.142 Y 6 Lipid phosphate phosphohydrolase 2 
P55011 S12A2_HUMAN SLC12A2   1 1 7.98E+05 7.20E+05 0.149 Y 12 Solute carrier family 12 member 2 
O75144 ICOSL_HUMAN ICOSLG CD275 1 1 4.64E+04 4.18E+04 0.152 Y 1 ICOS ligand 
Q6PIU2 NCEH1_HUMAN NCEH1   3 3 2.49E+05 2.22E+05 0.169   0 Neutral cholesterol ester hydrolase 1 
Q9H0X4 ITFG3_HUMAN ITFG3   3 3 6.16E+05 5.44E+05 0.179   1 Protein ITFG3 
Q7KYR7 BT2A1_HUMAN BTN2A1   1 1 1.47E+04 1.28E+04 0.191 Y 1 Butyrophilin subfamily 2 member A1 
P52799 EFNB2_HUMAN EFNB2   1 1 2.47E+04 2.15E+04 0.199 Y 1 Ephrin-B2 
P12830 CADH1_HUMAN CDH1 CD324 4 4 5.59E+05 4.80E+05 0.221 Y 1 Cadherin-1 
Q14126 DSG2_HUMAN DSG2   7 7 1.45E+06 1.24E+06 0.221   1 Desmoglein-2 
Q9NTN9 
SEM4G_HUMA
N SEMA4G   1 1 1.23E+04 1.06E+04 0.221 Y 1 Semaphorin-4G 
P05362 ICAM1_HUMAN ICAM1 CD54 4 4 9.49E+05 8.06E+05 0.236 Y 1 Intercellular adhesion molecule 1 
P40189 IL6RB_HUMAN IL6ST CD130 5 5 2.56E+05 2.16E+05 0.249 Y 1 Interleukin-6 receptor subunit beta 
Q15043 S39AE_HUMAN SLC39A14   1 1 1.44E+05 1.19E+05 0.272 Y 6 Zinc transporter ZIP14 
Q15165 PON2_HUMAN PON2   3 3 1.76E+05 1.45E+05 0.279   0 Serum paraoxonase\arylesterase 2 
O60635 TSN1_HUMAN TSPAN1   2 2 1.08E+05 8.78E+04 0.295 Y 4 Tetraspanin-1 
P16278 BGAL_HUMAN GLB1   5 5 2.15E+05 1.73E+05 0.309   0 Beta-galactosidase 
Q13641 TPBG_HUMAN TPBG   5 5 8.75E+05 7.04E+05 0.314 Y 1 Trophoblast glycoprotein 
Q5NDL2 AER61_HUMAN AER61   1 1 9.45E+03 7.54E+03 0.327   0 Uncharacterized glycosyltransferase AER61 
Q12797 ASPH_HUMAN ASPH   2 2 1.12E+06 8.53E+05 0.388   1 Aspartyl\asparaginyl beta-hydroxylase 
Q969V3 NCLN_HUMAN NCLN   1 1 1.17E+05 8.97E+04 0.389 Y 2 Nicalin 
Q9Y487 VPP2_HUMAN ATP6V0A2   2 2 3.26E+04 2.45E+04 0.412 Y 8 V-type proton ATPase 116 kDa subunit a isoform 2 
P26006 ITA3_HUMAN ITGA3 CD49c 8 7 1.25E+06 9.31E+05 0.424 Y 1 Integrin alpha-3 
O15118 NPC1_HUMAN NPC1   4 4 1.95E+05 1.45E+05 0.432   13 Niemann-Pick C1 protein 
P16422 
EPCAM_HUMA
N EPCAM CD326 10 10 4.64E+06 3.40E+06 0.450   1 Epithelial cell adhesion molecule 
Q9Y6H6 KCNE3_HUMAN KCNE3   1 1 3.59E+04 2.60E+04 0.465 Y 1 Potassium voltage-gated channel subfamily E member 3 
P07711 CATL1_HUMAN CTSL1   1 1 2.03E+04 1.46E+04 0.481   0 Cathepsin L1 
O14672 ADA10_HUMAN ADAM10 CD156c 3 3 1.19E+06 8.53E+05 0.483 Y 1 Disintegrin and metalloproteinase domain-containing protein 10 
Q8IWB1 IPRI_HUMAN ITPRIP   1 1 3.25E+04 2.30E+04 0.497   0 Inositol 1,4,5-triphosphate receptor-interacting protein 
Q14002 
CEAM7_HUMA
N CEACAM7   2 2 5.70E+04 4.03E+04 0.498   1, GPI Carcinoembryonic antigen-related cell adhesion molecule 7 
P18564 ITB6_HUMAN ITGB6   1 1 2.55E+04 1.80E+04 0.504 Y 1 Integrin beta-6 
Q5T3F8 TM63B_HUMAN TMEM63B   1 1 1.00E+04 7.04E+03 0.507 Y 11 Transmembrane protein 63B 
Q9Y6M7 S4A7_HUMAN SLC4A7   2 2 8.51E+04 5.85E+04 0.540 Y 11 Sodium bicarbonate cotransporter 3 
O43921 EFNA2_HUMAN EFNA2   2 1 9.03E+04 6.20E+04 0.542   GPI Ephrin-A2 
P29323 EPHB2_HUMAN EPHB2   1 1 1.07E+05 7.24E+04 0.569 Y 1 Ephrin type-B receptor 2 
Q9P2B2 FPRP_HUMAN PTGFRN CD315 7 7 9.78E+05 6.48E+05 0.594 Y 1 Prostaglandin F2 receptor negative regulator 
P16144 ITB4_HUMAN ITGB4 CD104 8 8 1.53E+06 1.01E+06 0.595   1 Integrin beta-4 
Q8NC42 RN149_HUMAN RNF149   1 1 5.25E+04 3.47E+04 0.597 Y 1 E3 ubiquitin-protein ligase RNF149 
Q96PB1 CASD1_HUMAN CASD1   2 2 3.56E+04 2.32E+04 0.618 Y 14 CAS1 domain-containing protein 1 
Q6P9F7 LRC8B_HUMAN LRRC8B   1 1 2.57E+04 1.67E+04 0.626 Y 4 Leucine-rich repeat-containing protein 8B 
Q02487 DSC2_HUMAN DSC2   1 1 1.21E+05 7.71E+04 0.645   1 Desmocollin-2 
Q9NUM4 T106B_HUMAN TMEM106B   2 2 3.40E+04 2.17E+04 0.648 Y 1 Transmembrane protein 106B 
O75054 IGSF3_HUMAN IGSF3   5 5 8.01E+05 5.08E+05 0.657 Y 1 Immunoglobulin superfamily member 3 
Q58DX5 NADL2_HUMAN NAALADL2   1 1 2.14E+04 1.34E+04 0.680 Y 1 Inactive N-acetylated-alpha-linked acidic dipeptidase-like protein 2 
Q92485 ASM3B_HUMAN SMPDL3B   1 1 2.36E+03 1.48E+03 0.680   0 Acid sphingomyelinase-like phosphodiesterase 3b 
Q9H5V8 CDCP1_HUMAN CDCP1 CD318 4 4 1.97E+05 1.22E+05 0.692 Y 1 CUB domain-containing protein 1 
Q96AP7 ESAM_HUMAN ESAM   1 1 3.19E+04 1.92E+04 0.730 Y 1 Endothelial cell-selective adhesion molecule 
Q29983 MICA_HUMAN MICA   2 1 2.49E+04 1.50E+04 0.731 Y 1 MHC class I polypeptide-related sequence A 
O60779 S19A2_HUMAN SLC19A2   1 1 2.05E+05 1.24E+05 0.733 Y 12 Thiamine transporter 1 
P21709 EPHA1_HUMAN EPHA1   3 3 1.72E+05 1.00E+05 0.786 Y 1 Ephrin type-A receptor 1 
P16070 CD44_HUMAN CD44 CD44 4 3 3.11E+06 1.80E+06 0.791 Y 1 CD44 antigen 
Q96K49 TM87B_HUMAN TMEM87B   2 2 1.61E+05 9.31E+04 0.791 Y 7 Transmembrane protein 87B 
Q53GD3 CTL4_HUMAN SLC44A4   1 1 5.30E+03 3.03E+03 0.805 Y 10 Choline transporter-like protein 4 
Q14118 DAG1_HUMAN DAG1   2 1 3.34E+04 1.89E+04 0.824 Y 1 Dystroglycan 
P06865 HEXA_HUMAN HEXA   1 1 4.64E+04 2.57E+04 0.854   0 Beta-hexosaminidase subunit alpha 
Q3MIR4 CC50B_HUMAN TMEM30B   4 4 9.93E+04 5.16E+04 0.945 Y 2 Cell cycle control protein 50B 
Q9HDC9 
APMAP_HUMA
N APMAP   4 4 6.31E+05 3.24E+05 0.963   1 Adipocyte plasma membrane-associated protein 
Q9Y4L1 
HYOU1_HUMA
N HYOU1   14 13 6.42E+06 3.27E+06 0.972   0 Hypoxia up-regulated protein 1 
Q92854 
SEM4D_HUMA
N SEMA4D CD100 4 3 1.46E+05 7.44E+04 0.973 Y 1 Semaphorin-4D 
P13866 SC5A1_HUMAN SLC5A1   1 1 1.78E+05 9.05E+04 0.978 Y 14 Sodium\glucose cotransporter 1 
Q68CR1 SE1L3_HUMAN SEL1L3   2 2 2.86E+04 1.44E+04 0.992   1 Protein sel-1 homolog 3 
Q9H8M5 
CNNM2_HUMA
N CNNM2   2 2 3.86E+04 1.91E+04 1.013 Y 4 Metal transporter CNNM2 
Q5JRA6 MIA3_HUMAN MIA3   5 5 2.32E+05 1.15E+05 1.014   2 Melanoma inhibitory activity protein 3 
P06756 ITAV_HUMAN ITGAV CD51 9 9 4.87E+06 2.37E+06 1.041 Y 1 Integrin alpha-V 
Q9Y2B1 
TMEM5_HUMA
N TMEM5   1 1 3.85E+04 1.87E+04 1.042   0 Transmembrane protein 5 
P35052 GPC1_HUMAN GPC1   1 1 1.25E+04 5.99E+03 1.058   1, GPI Glypican-1 
Q01973 ROR1_HUMAN ROR1   1 1 4.32E+03 2.06E+03 1.068 Y 2 Tyrosine-protein kinase transmembrane receptor ROR1 
O95858 TSN15_HUMAN TSPAN15   2 2 2.13E+05 9.86E+04 1.109 Y 5 Tetraspanin-15 
Q12866 
MERTK_HUMA
N MERTK   2 1 1.10E+04 4.90E+03 1.170 Y 1 Tyrosine-protein kinase Mer 
Q08722 CD47_HUMAN CD47 CD47 2 2 1.38E+05 6.08E+04 1.184 Y 5 Leukocyte surface antigen CD47 
O43157 PLXB1_HUMAN PLXNB1   1 1 1.78E+05 7.67E+04 1.214   1 Plexin-B1 
Q99571 P2RX4_HUMAN P2RX4   1 1 9.74E+03 4.16E+03 1.227 Y 2 P2X purinoceptor 4 
O60487 MPZL2_HUMAN MPZL2   1 1 1.83E+05 7.46E+04 1.294   1 Myelin protein zero-like protein 2 
Q13444 ADA15_HUMAN ADAM15   1 1 7.23E+04 2.86E+04 1.336 Y 1 Disintegrin and metalloproteinase domain-containing protein 15 
O15031 PLXB2_HUMAN PLXNB2   14 14 4.53E+06 1.71E+06 1.401   1 Plexin-B2 
P10646 TFPI1_HUMAN TFPI   1 1 5.78E+04 2.14E+04 1.431   0 Tissue factor pathway inhibitor 
Q04771 ACVR1_HUMAN ACVR1   1 1 4.02E+04 1.45E+04 1.474 Y 1 Activin receptor type-1 
Q92508 FA38A_HUMAN FAM38A   1 1 2.13E+05 7.53E+04 1.500 Y 29 Protein FAM38A 
Q68D85 YK047_HUMAN     1 1 5.62E+04 1.98E+04 1.505     
Putative Ig-like domain-containing protein DKFZp686O24166\DKFZp686I21167  
SV=1 
P23229 ITA6_HUMAN ITGA6 CD49f 10 10 6.26E+06 2.17E+06 1.530 Y 1 Integrin alpha-6 
P19256 LFA3_HUMAN CD58 CD58 3 3 7.16E+05 2.47E+05 1.539 Y 1, GPI Lymphocyte function-associated antigen 3 
Q07954 LRP1_HUMAN LRP1 CD91 9 9 4.27E+05 1.43E+05 1.581 Y 1 Prolow-density lipoprotein receptor-related protein 1 
Q6UXD5 SE6L2_HUMAN SEZ6L2   3 3 2.87E+05 9.53E+04 1.589 Y 1 Seizure 6-like protein 2 
P16444 DPEP1_HUMAN DPEP1   2 2 4.89E+04 1.57E+04 1.639   1, GPI Dipeptidase 1 
O43490 
PROM1_HUMA
N PROM1 CD133 7 7 9.93E+05 3.17E+05 1.646 Y 5 Prominin-1 
Q8WTV0 SCRB1_HUMAN SCARB1   1 1 4.32E+04 1.31E+04 1.727 Y 1 Scavenger receptor class B member 1 
P43308 SSRB_HUMAN SSR2   2 2 4.24E+04 1.28E+04 1.733   1 Translocon-associated protein subunit beta 
P48960 CD97_HUMAN CD97 CD97 2 2 7.63E+04 2.18E+04 1.805 Y 7 CD97 antigen 
Q99988 GDF15_HUMAN GDF15   1 1 1.27E+05 3.60E+04 1.815   0 Growth\differentiation factor 15 
P35527 K1C9_HUMAN KRT9   1 1 7.91E+03 1.93E+03 2.034   0 Keratin, type I cytoskeletal 9 
P08174 DAF_HUMAN CD55 CD55 1 1 1.31E+05 3.02E+04 2.117   GPI Complement decay-accelerating factor 
Q13740 CD166_HUMAN ALCAM CD166 5 5 1.73E+06 3.95E+05 2.135 Y 1 CD166 antigen 
Q13308 PTK7_HUMAN PTK7   1 1 5.95E+04 1.30E+04 2.193 Y 1 Tyrosine-protein kinase-like 7 
P07942 LAMB1_HUMAN LAMB1   4 4 1.00E+05 2.14E+04 2.233   0 Laminin subunit beta-1 
Q9Y4D7 PLXD1_HUMAN PLXND1   1 1 5.87E+04 1.25E+04 2.236 Y 1 Plexin-D1 
O60637 TSN3_HUMAN TSPAN3   1 1 1.95E+04 3.70E+03 2.399 Y 4 Tetraspanin-3 
P33527 MRP1_HUMAN ABCC1   4 4 4.54E+05 8.36E+04 2.441 Y 16 Multidrug resistance-associated protein 1 
Q9Y5L3 ENTP2_HUMAN ENTPD2   2 2 3.00E+05 5.35E+04 2.485 Y 1 Ectonucleoside triphosphate diphosphohydrolase 2 
P15260 INGR1_HUMAN IFNGR1 CD119 1 1 3.04E+03 5.01E+02 2.602 Y 1 Interferon gamma receptor 1 
Q08174 PCDH1_HUMAN PCDH1   1 1 8.03E+04 1.22E+04 2.720 Y 1 Protocadherin-1 
Q8N4M1 CTL3_HUMAN SLC44A3   1 1 1.16E+04 1.65E+03 2.814 Y 9 Choline transporter-like protein 3 
P10909 CLUS_HUMAN CLU   2 2 2.11E+05 2.66E+04 2.986   0 Clusterin 
Q6UVK1 CSPG4_HUMAN CSPG4   1 1 2.86E+05 3.20E+04 3.161 Y 1 Chondroitin sulfate proteoglycan 4 
P19075 TSN8_HUMAN TSPAN8   4 4 3.40E+07 3.57E+06 3.251 Y 4 Tetraspanin-8 
O43278 SPIT1_HUMAN SPINT1   2 2 2.19E+05 2.29E+04 3.257 Y 1 Kunitz-type protease inhibitor 1 
P06213 INSR_HUMAN INSR CD220 3 3 1.60E+05 1.53E+04 3.382 Y 1 Insulin receptor 
Q15155 
NOMO1_HUMA
N NOMO1   2 1 6.01E+04 5.21E+03 3.527   1 Nodal modulator 1 
P78504 JAG1_HUMAN JAG1 CD339 1 1 2.01E+05 1.61E+04 3.642 Y 1 Protein jagged-1 
P27487 DPP4_HUMAN DPP4 CD26 4 4 1.04E+05 8.02E+03 3.702   0 Dipeptidyl peptidase 4 
Q9UM44 HHLA2_HUMAN HHLA2   1 1 9.07E+04 6.60E+03 3.780 Y 1 HERV-H LTR-associating protein 2 
O43570 CAH12_HUMAN CA12   4 4 1.23E+06 6.84E+04 4.165 Y 1 Carbonic anhydrase 12 
P98088 
MUC5A_HUMA
N MUC5AC   2 2 8.05E+04 4.07E+03 4.304   0 Mucin-5AC (Fragments) 
P13726 TF_HUMAN F3 CD142 1 1 5.34E+04 1.26E+03 5.407 Y 1, GPI Tissue factor 
P06731 
CEAM5_HUMA
N CEACAM5 CD66e 6 6 2.47E+06 1.75E+04 7.145   1, GPI Carcinoembryonic antigen-related cell adhesion molecule 5 
Q96J84 KIRR1_HUMAN KIRREL   1 1 2.47E+04 3.22E+01 9.583 Y 1 Kin of IRRE-like protein 1 
 

